CN111362832B - 环丙烷类化合物及其制备方法和应用 - Google Patents
环丙烷类化合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN111362832B CN111362832B CN201811602169.9A CN201811602169A CN111362832B CN 111362832 B CN111362832 B CN 111362832B CN 201811602169 A CN201811602169 A CN 201811602169A CN 111362832 B CN111362832 B CN 111362832B
- Authority
- CN
- China
- Prior art keywords
- substituted
- heterocycloalkyl
- group
- alkyl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Cyclopropane compound Chemical class 0.000 title claims abstract description 137
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 150000001942 cyclopropanes Chemical class 0.000 claims abstract description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 390
- 238000006243 chemical reaction Methods 0.000 claims description 237
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 131
- 125000000217 alkyl group Chemical group 0.000 claims description 119
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 110
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 101
- 125000003118 aryl group Chemical group 0.000 claims description 75
- 239000002904 solvent Substances 0.000 claims description 74
- 125000005842 heteroatom Chemical group 0.000 claims description 64
- 229910052786 argon Inorganic materials 0.000 claims description 55
- 239000003446 ligand Substances 0.000 claims description 54
- 125000000304 alkynyl group Chemical group 0.000 claims description 53
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 52
- 229910052799 carbon Inorganic materials 0.000 claims description 52
- PENAXHPKEVTBLF-UHFFFAOYSA-L palladium(2+);prop-1-ene;dichloride Chemical compound [Pd+]Cl.[Pd+]Cl.[CH2-]C=C.[CH2-]C=C PENAXHPKEVTBLF-UHFFFAOYSA-L 0.000 claims description 50
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 49
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 48
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 48
- 125000001072 heteroaryl group Chemical group 0.000 claims description 46
- 150000001875 compounds Chemical class 0.000 claims description 44
- 229910052736 halogen Inorganic materials 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 39
- 150000002367 halogens Chemical class 0.000 claims description 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 229910052763 palladium Inorganic materials 0.000 claims description 24
- 239000003960 organic solvent Substances 0.000 claims description 19
- 150000005840 aryl radicals Chemical class 0.000 claims description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 229940126062 Compound A Drugs 0.000 claims description 13
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 13
- 229910052783 alkali metal Inorganic materials 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- ADLVDYMTBOSDFE-UHFFFAOYSA-N 5-chloro-6-nitroisoindole-1,3-dione Chemical compound C1=C(Cl)C([N+](=O)[O-])=CC2=C1C(=O)NC2=O ADLVDYMTBOSDFE-UHFFFAOYSA-N 0.000 claims description 12
- 239000003054 catalyst Substances 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 6
- 150000001335 aliphatic alkanes Chemical class 0.000 claims description 6
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 6
- 239000007789 gas Substances 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910000288 alkali metal carbonate Inorganic materials 0.000 claims description 5
- 150000008041 alkali metal carbonates Chemical class 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 claims description 5
- 230000001681 protective effect Effects 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 4
- 229910052709 silver Inorganic materials 0.000 claims description 4
- 239000004332 silver Substances 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 2
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 claims description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical group [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 2
- 229910052743 krypton Inorganic materials 0.000 claims description 2
- DNNSSWSSYDEUBZ-UHFFFAOYSA-N krypton atom Chemical compound [Kr] DNNSSWSSYDEUBZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 229910052754 neon Inorganic materials 0.000 claims description 2
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 2
- 125000005981 pentynyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 claims description 2
- 229910052704 radon Inorganic materials 0.000 claims description 2
- SYUHGPGVQRZVTB-UHFFFAOYSA-N radon atom Chemical compound [Rn] SYUHGPGVQRZVTB-UHFFFAOYSA-N 0.000 claims description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 2
- 229910052724 xenon Inorganic materials 0.000 claims description 2
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- 150000003254 radicals Chemical class 0.000 claims 3
- 125000001033 ether group Chemical group 0.000 claims 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical group C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 claims 2
- UKSZBOKPHAQOMP-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1.C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 UKSZBOKPHAQOMP-UHFFFAOYSA-N 0.000 claims 1
- MXJGZAMERDEUKM-UHFFFAOYSA-N N[Li].C[Si](N[Si](C)(C)C)(C)C Chemical compound N[Li].C[Si](N[Si](C)(C)C)(C)C MXJGZAMERDEUKM-UHFFFAOYSA-N 0.000 claims 1
- QFIRONPERRUJAN-UHFFFAOYSA-N [NH2-].[Na+].C[Si](N[Si](C)(C)C)(C)C Chemical compound [NH2-].[Na+].C[Si](N[Si](C)(C)C)(C)C QFIRONPERRUJAN-UHFFFAOYSA-N 0.000 claims 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 239000000758 substrate Substances 0.000 abstract description 9
- IDITVISEENJSMD-UHFFFAOYSA-N cyclopropylidenemethanone Chemical class O=C=C1CC1 IDITVISEENJSMD-UHFFFAOYSA-N 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 description 89
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 52
- 238000004440 column chromatography Methods 0.000 description 51
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 239000000203 mixture Substances 0.000 description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 38
- ADZWSOLPGZMUMY-UHFFFAOYSA-M silver bromide Chemical compound [Ag]Br ADZWSOLPGZMUMY-UHFFFAOYSA-M 0.000 description 35
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 22
- 238000010791 quenching Methods 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 239000013078 crystal Substances 0.000 description 11
- 230000009897 systematic effect Effects 0.000 description 11
- AGKLVMVJXDFIGC-MDZDMXLPSA-N tert-butyl (e)-3-phenylprop-2-enoate Chemical compound CC(C)(C)OC(=O)\C=C\C1=CC=CC=C1 AGKLVMVJXDFIGC-MDZDMXLPSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 7
- 230000000171 quenching effect Effects 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 239000003638 chemical reducing agent Substances 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 125000006548 C4-10 heterocycloalkyl group Chemical group 0.000 description 5
- 238000006722 reduction reaction Methods 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- 229910010082 LiAlH Inorganic materials 0.000 description 4
- 238000007259 addition reaction Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- 125000006546 (C4-C10) cycloalkyl group Chemical group 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000004795 grignard reagents Chemical class 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- UZQQCYKWZUXRCV-JXMROGBWSA-N tert-butyl [(e)-3-phenylprop-2-enyl] carbonate Chemical compound CC(C)(C)OC(=O)OC\C=C\C1=CC=CC=C1 UZQQCYKWZUXRCV-JXMROGBWSA-N 0.000 description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 2
- 150000004696 coordination complex Chemical class 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 description 1
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 1
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 1
- KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 229910021612 Silver iodide Inorganic materials 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- TWKVUTXHANJYGH-UHFFFAOYSA-L allyl palladium chloride Chemical compound Cl[Pd]CC=C.Cl[Pd]CC=C TWKVUTXHANJYGH-UHFFFAOYSA-L 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000005888 cyclopropanation reaction Methods 0.000 description 1
- AUQDITHEDVOTCU-UHFFFAOYSA-N cyclopropyl cyanide Chemical class N#CC1CC1 AUQDITHEDVOTCU-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229940045105 silver iodide Drugs 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- NBRKLOOSMBRFMH-UHFFFAOYSA-N tert-butyl chloride Chemical compound CC(C)(C)Cl NBRKLOOSMBRFMH-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/44—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers
- C07C209/48—Preparation of compounds containing amino groups bound to a carbon skeleton by reduction of carboxylic acids or esters thereof in presence of ammonia or amines, or by reduction of nitriles, carboxylic acid amides, imines or imino-ethers by reduction of nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/02—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C255/03—Mononitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/06—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms of an acyclic and unsaturated carbon skeleton
- C07C255/07—Mononitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/31—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
- C07F7/083—Syntheses without formation of a Si-C bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
本发明公开了一种环丙烷类化合物及其制备方法和应用。本发明如式I所示的环丙烷类化合物的制备方法具有底物适用广,能够简单、高效地得到多种类型的环丙烷类化合物。本发明如式I所示的环丙烷类化合物可用来制备环丙烷伯胺类化合物、环丙烷酮类化合物或者环内酰胺类化合物。
Description
技术领域
本发明涉及一种环丙烷类化合物及其制备方法和应用。
背景技术
环丙烷类化合物广泛存在于多种天然产物和药物分子中(Chem.Soc.Rev.1978,7,473.;Tetrahedron 2001,57,8589.;Chem.Rev.2003,103,1625.;Chem.Rev.2007,107,4493.)。目前,该类化合物的制备方法主要为,在钯催化下,亲核试剂与烯丙基底物进行反应。上述方法是构建此类化合物的一种行之有效的方法。但是,现有的成熟的反应体系较少,底物适用性窄,故其应用也受到了限制。因此,开发一种新型、简便、应用面广的方法合成环丙烷化合物具有重要的工业意义。
现有技术中,一般采用含有α-H的酯、酮或者酰胺等羧酸衍生物与烯丙基化合物进行反应制备环丙烷化合物(J.Am.Chem.Soc.1998,120,10391.;Tetrahedron Lett.1999,40,3597.;J.Am.Chem.Soc.2009,131,8734.;J.Org.Chem.2014,79,12010.;AsianJ.Org.Chem.2017,6,1769.)。文献(Angew.Chem.,Int.Ed.Engl.1992,31,234.)报道了2-丙氰与金属络合物来制备氰基环丙烷化合物,其中得到的产物中苯基位于环丙烷的同侧;但是含有氰基的底物适用性窄,另一底物还需为金属络合物1,而且合成步骤较多,反应效率不高,生产成本较大。其反应过程如下:
在现有的方法中,烯丙基化合物多为芳基或者烯基取代烯丙基化合物,种类单一。
鉴于环丙烷类化合物的重要性,亟须开发一种底物适用性广、合成步骤少、反应收率高的环丙烷类化合物制备方法,从而高效制备结构类型多样化的环丙烷类化合物。
发明内容
本发明所要解决的技术问题是为了克服现有技术中钯催化环丙烷化反应中反应体系复杂、产物结构单一、生产成本大和收率不高等缺陷,而提供了一种如式I所示的环丙烷类化合物及其制备方法和应用。本发明如式I所示的环丙烷类化合物的制备方法具有底物适用广、反应条件温和后处理简单,能够简单、高效地得到多种类型的环丙烷类化合物。本发明如式I所示的环丙烷类化合物可用来制备环丙烷伯胺类化合物、环丙烷酮类化合物或者环内酰胺类化合物。
本发明通过以下技术方案解决上述技术问题。
本发明提供了一种如式I所示的环丙烷类化合物,
其中,R1和R2独立地为直链C1-10烷基、R1-1取代的直链C1-10烷基、支链C3-10烷基、R1-2取代的支链C3-10烷基、C3-10环烷基、R1-3取代的C3-10环烷基、C3-10杂环烷基、或、R1-4取代的C3-10杂环烷基;所述C3-10杂环烷基为杂原子选自N、O和S中一种或多种,杂原子数为1~4个的C3-10杂环烷基;所述R1-4取代的C3-10杂环烷基中的C3-10杂环烷基为杂原子选自N、O和S中一种或多种,杂原子数为1~4个的C3-10杂环烷基;
R1-1和R1-2独立地为卤素或羟基;R1-3和R1-4独立地为卤素、羟基、直链C1-10烷基、支链C3-10烷基或C1-10烷氧基;
或者,R1、R2及与它们相连的碳一起形成C3-10环烷基、R2-1取代的C3-10环烷基、C3-10杂环烷基、或、R2-2取代的C3-10杂环烷基;所述C3-10杂环烷基为杂原子选自N、O和S中一种或多种,杂原子数为1~4个的C3-10杂环烷基;所述R2-2取代的C3-10杂环烷基中的C3-10杂环烷基为杂原子选自N、O和S中一种或多种,杂原子数为1~4个的C3-10杂环烷基;
R3为C1-10烷氧基、C6-30芳基、R3-1取代的C6-30芳基、C3-30杂芳基、R3-2取代的C3-30杂芳基、C2-10炔基、R3-3取代的C2-10炔基、所述C3-30杂芳基为杂原子选自N、O和S中一种或多种,杂原子数为1~4个的C3-30杂芳基;所述R3-2取代的C3-30杂芳基中的C3-30杂芳基为杂原子选自N、O和S中一种或多种,杂原子数为1~4个的C3-30杂芳基;
R3-1和R3-2独立地为直链C1-10烷基、支链C3-10烷基、C1-10烷氧基、卤素、硝基或氰基;R3-3独立地为卤素、C2-10烯基、C1-10烷氧基、C6-30芳基、苯氧基或R3-3-1取代的C6-30芳基;R3-4独立地为C6-30芳基、或、R3-4-1取代的C6-30芳基;R3-5a、R3-5b和R3-5c独立地为直链C1-10烷基或支链C3-10烷基;
R3-3-1和R3-4-1独立地为直链C1-10烷基、支链C3-10烷基、C1-10烷氧基或卤素;
R1-1、R1-2、R1-3、R1-4、R2-1、R2-2、R3-1、R3-2、R3-3、R3-3-1和R3-4-1的个数独立地为1个或多个;当R1-1、R1-2、R1-3、R1-4、R2-1、R2-2、R3-1、R3-2、R3-3、R3-3-1和R3-4-1的个数独立地为多个时,R1-1、R1-2、R1-3、R1-4、R2-1、R2-2、R3-1、R3-2、R3-3、R3-3-1和R3-4-1独立地相同或不同。
所述如式I所示的环丙烷类化合物可为如下所示:
R1和R2中,所述直链C1-10烷基优选直链C1-6烷基,更优选直链C1-3烷基。所述直链C1-3烷基为甲基、乙基或正丙基,优选甲基或乙基。
R1和R2中,所述R1-1取代的直链C1-10烷基中的直链C1-10烷基优选直链C1-6烷基,更优选直链C1-3烷基。
R1和R2中,所述支链C3-10烷基和R1-2取代的支链C3-10烷基中的支链C3-10烷基独立地优选支链C3-6烷基。
R1和R2中,所述C3-10环烷基优选C4-10环烷基,更优选C4-7环烷基。所述C4-7环烷基进一步优选环丁基、环戊基、环己基或环庚基,优选环己基或环庚基。
R1和R2中,所述R2-1取代的C3-10环烷基中的C3-10环烷基优选C4-10环烷基,更优选C4-7环烷基。
R1和R2中,所述C3-10杂环烷基和所述R1-4取代的C3-10杂环烷基中的C3-10杂环烷基独立地优选C4-10杂环烷基,更优选C4-6杂环烷基。
当R1为直链C1-10烷基、R1-1取代的直链C1-10烷基、支链C3-10烷基或R1-2取代的支链C3-10烷基时,R1和R2相同。
当R1、R2及与它们相连的碳一起形成C3-10环烷基时,所述C3-10环烷基优选C4-10环烷基,更优选C4-7环烷基。
当R1、R2及与它们相连的碳一起形成C3-10杂环烷基时,所述C3-10杂环烷基优选C4-10杂环烷基,更优选C4-6杂环烷基,进一步优选杂环己基。
当R1、R2及与它们相连的碳一起形成C3-10杂环烷基时,所述C3-10杂环烷基中的杂原子优选O和/或N,更优选O。
当R1、R2及与它们相连的碳一起形成C3-10杂环烷基时,所述C3-10杂环烷基中的杂原子的个数优选1个或2个,更优选1个。当所述杂原子为多个时,杂原子可相同或不同。
当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2取代的C3-10杂环烷基中的C3-10杂环烷基优选C4-10杂环烷基,更优选C4-6杂环烷基,进一步优选杂环己基。
当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2取代的C3-10杂环烷基中的杂原子优选O和/或N,更优选N。
当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2取代的C3-10杂环烷基中的杂原子的个数为1或2,更优选1。当所述杂原子为多个时,杂原子可相同或不同。
当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2取代的C3-10杂环烷基中的C3-10杂环烷基优选C4-10杂环烷基,优选的C4-6杂环烷基,进一步哌啶基。
当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2独立地优选卤素、直链C1-10烷基、支链C3-10烷基、C1-10烷氧基或更优选R2m中,所述的C1-4烷基优选甲基、乙基、正丙基、异丙基、正丁基、异丁基或叔丁基,优选叔丁基。
当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2的个数优选1、2或3,更优选1。当所述R2-2为多个时,R2-2可相同或不同。
R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基,所述R2-2取代的C3-10杂环烷基优选“卤素、直链C1-10烷基、支链C3-10烷基、C1-10烷氧基或个数为1个、2个或3个”取代的“杂原子为O或N,个数为1或2个”的C4-10杂环烷基,更优选“个数为1”取代的“杂原子为N,个数为1”的C4-6杂环烷基,进一步优选
R3中,所述C6-30芳基和所述R3-1取代的C6-30芳基中的C6-30芳基独立地可为C6-14芳基,优选C6-10芳基,进一步优选苯基或萘基。
R3中,所述R3-1取代的C6-30芳基中的R3-1独立地优选卤素、直链C1-10烷基、支链C3-10烷基或C1-10烷氧基,优选直链C1-10烷基。
R3中,所述R3-1取代的C6-30芳基中的R3-1的个数优选1、2或3个,更优选1个。当所述R3-1为多个时,所述R3-1相同或不同。
R3中,所述R3-1取代的C6-30芳基中的R3-1取代位置优选“芳基与其它基团连接位点”的邻位和/或对位,更优选对位。
R3中,所述R3-1取代的C6-30芳基优选“卤素、直链C1-10烷基、支链C3-10烷基或C1-10烷氧基,个数为1、2或3个,“芳基与其它基团连接位点”的邻位和/或对位”取代的C6-14芳基,更优选“直链C1-10烷基,个数为1个,对位”取代的C6-10芳基,进一步优选
R3-1中,所述直链C1-10烷基优选直链C1-6烷基,更优选直链C1-3烷基,进一步优选甲基。
R3-1中,所述支链C3-10烷基优选支链C3-6烷基,更优选支链C3-4烷基,进一步优选异丙基。
R3-1中,所述C1-10烷氧基优选C1-6烷氧基,更优选C1-3烷氧基,进一步优选甲氧基。
R3中,所述C3-30杂芳基优选C6-14杂芳基,更优选C6-10杂芳基。
R3中,所述C3-30杂芳基中的杂原子的种类优选N和/或O,更优选O。
R3中,所述C3-30杂芳基中的杂原子的个数优选1或2,更优选1。当所述杂原子的个数为多个时,杂原子可相同或不同。
R3中,所述R3-3取代的C2-10炔基中C2-10炔基优选C2-7炔基,更优选C2-5炔基,进一步优选乙炔基、丙炔基、丁炔基或戊炔基。
R3中,所述R3-3取代的C2-10炔基中的R3-3优选卤素、C2-10烯基、C6-30芳基或苯氧基,更优选卤素或C2-10烯基。
R3中,所述R3-3取代的C2-10炔基中的R3-3的个数为1、2或3,优选1个。当所述R3-3的个数为多个时,R3-3可相同或不同。
R3中,所述R3-3取代的C2-10炔基优选“卤素、C2-10烯基、C6-30芳基或苯氧基,个数为1、2或3个”取代的C2-7炔基,更优选“卤素或C2-10烯基,个数为1个”取代的C2-5炔基,进一步优选
R3-3中,所述卤素优选F、Cl、Br或I,更优选Cl。
R3-3中,所述C2-10烯基优选C2-6烯基,更优选C2-3烯基,进一步优选乙烯基。
R3-3中,所述C6-30芳基优选C6-14芳基,更优选C6-10芳基,进一步优选苯基。
R3-4中,所述C6-30芳基优选C6-14芳基,更优选C6-10芳基,进一步优选苯基。
R3-5a、R3-5b和R3-5c中,所述直链C1-10烷基独立地优选直链C1-6烷基,优选直链C1-3烷基,进一步优选甲基。
在某一技术方案中,R1和R2独立地优选C1-10烷基或C3-10环烷基,更优C1-10烷基。
在某一技术方案中,R1和R2独立优选甲基、乙基或环己基,更优选甲基或乙基。
在某一技术方案中,R1、R2及与它们相连的碳一起形成C3-10环烷基、C3-10杂环烷基或R2-2取代的C3-10杂环烷基,更优选R1、R2及与它们相连的碳一起形成C3-10环烷基,最优选R1、R2及与它们相连的碳一起形成C4-7环烷基。
在某一技术方案中,R3为C6-30芳基、R3-1取代的C6-30芳基、C3-30杂芳基、C2-10炔基、R3-3取代的C2-10炔基、优选C6-30芳基、R3-1取代的C6-30芳基、C3-30杂芳基、C2-10炔基或R3-3取代的C2-10炔基。
在某一技术方案中,R1和R2独立地为C1-10烷基或C3-10环烷基;或者,R1、R2及与它们相连的碳一起形成C3-10环烷基、C3-10杂环烷基或R2-2取代的C3-10杂环烷基;
在某一技术方案中,R1和R2为C1-10烷基,或者R1、R2及与它们相连的碳一起形成C3-10环烷基;
和,R3为C6-30芳基、R3-1取代的C6-30芳基、C3-30杂芳基、C2-10炔基或R3-3取代的C2-10炔基。
在某一技术方案中,所述如式I所示的环丙烷类化合物为如下化合物:
本发明还提供了一种如上如式I所示的环丙烷类化合物的制备方法,其包括以下步骤:在保护气体的存在中,在碱性试剂、氮杂环卡宾配体与钯催化剂存在下,将化合物A与化合物B在有机溶剂中进行如下式反应,得到如式I所示的环丙烷类化合物,即可;
其中,M+为K+、Na+或Li+。
其中,所述保护气体可为本领域常规的保护气体,优选氖气、氩气、氪气、氙气和氡气中的一种或多种,更优选氮气和/或氩气。
其中,所述碱性试剂可为本领域常规碱性试剂,优选六甲基二硅基胺基锂、六甲基二硅基胺基钠、二异丙基氨基锂、碱金属醇盐和碱金属碳酸盐一种或多种,更优选六甲基二硅基胺基锂或/或碱金属醇盐。所述碱金属醇盐可为RaONa、RbOK、RcOLi中的一种或多种,其中,Ra、Rb和Rc独立地为C1-4烷基;优选叔丁基。所述RaONa优选叔丁醇钠。所述RbOK优选叔丁醇钾。所述RcOLi优选叔丁醇锂。所述碱金属碳酸盐优选碳酸铯和/或碳酸钾。
其中,所述氮杂环卡宾配体可为本领域常规氮杂环卡宾配体,优选非手性氮杂环卡宾配体和/或手性氮杂环卡宾配体。所述非手性氮杂环卡宾配体可为中一种或多种,其中,X1、X2和X3独立地为卤素、OTf或BF4;Rd1、Rd2、Rd3、Rd4、Rd5、Re1、Re2、Re3、Re4、Re5、Rf1、Rf2、Rf3、Rf4、Rf5、Rs1、Rs2、Rs3、Rs4和Rs5独立地为H、C1-10烷基Ad为金刚烷基。所述卤素可为F、Cl、Br或I,优选Cl。所述C1-10烷基可为C1-6烷基,优选C1-4烷基。所述C1-4烷基可为甲基、乙基、丙基、异丙基、正丁基、异丁基或叔丁基,优选甲基或异丙基。
其中,所述手性氮杂环卡宾配体可为 中一种或多种,其中,X4、X5、和X6独立地为卤素、OTf或BF4;Rm1、Rm2、Rm3、Rm4、Rm5、Rn1、Rn2、Rn3、Rn4、Rn5、Ro1、Ro2、Ro3、Rq1、Rq2或Rq3独立地为H、C1-10烷基、所述卤素可为F、Cl、Br或I,优选Cl。所述C1-10烷基可为C1-6烷基,优选C1-4烷基。所述C1-4烷基可为甲基、乙基、丙基、异丙基、正丁基、异丁基或叔丁基,优选甲基。
其中,所述钯催化剂可为金属钯和/或钯络合物,优选钯络合物。所述钯络合物可为氯化烯丙基钯(II)二聚物、双二亚苄基丙酮钯、醋酸钯和氯化钯中的一种或多种,优选氯化烯丙基钯(II)二聚物。
其中,所述有机溶剂可为本领域此类反应种常规有机溶剂,优选醚类溶剂、芳烃类溶剂和烷烃类溶剂中的一种或多种。所述的醚类溶剂可为四氢呋喃、乙二醇二甲醚、乙醚和二氧六环中的一种或多种;优选四氢呋喃。所述的芳烃类溶剂可为甲苯。所述的烷烃类溶剂可为正己烷和/或环己烷;优选正己烷。
其中,所述碱性试剂与所述化合物B的摩尔比值可为本领域此类反应中的常规比值,优选0.1~0.5,优选0.1~0.2,例如0.125。
其中,所述氮杂环卡宾配体与所述化合物B的摩尔比值可为0.01-0.10,优选0.02~0.08,例如0.05。
其中,所述钯催化剂与所述化合物B的摩尔比值可为0.005~0.1,优选0.01~0.04,例如0.025。
其中,所述化合物A与所述的化合物B的摩尔比值可为1~5;优选2~5。
其中,所述有机溶剂的用量可不做具体限定,只要能够溶解底物,不影响反应即可。所述有机溶剂的体积与所述的化合物B的摩尔的体积摩尔比,优选10~20ml/mmol,例如14ml/mmol。
其中,所述反应的温度可为本领域此类反应的常规温度。优选-30℃~50℃,更优选-30℃~40℃。
所述反应的进程可采用本领域中的常规监测方法(例如TLC、或LC-MS)进行监测,一般以所述化合物B不再反应或消失为反应终点。所述反应时间可为1~50h,优选5~48h,例如12h。
所述反应结束后,还可包括下述后处理步骤:淬灭、浓缩和柱层析。所述淬灭的方法可为本领域此类反应的常规的淬灭方法。优选通过加入淬灭剂的方式进行淬灭。所述淬灭剂可为本领域常规的淬灭剂。优选水。所述浓缩的条件和操作可为本领域常规的条件和操作,优选减压浓缩。所述柱层析的洗脱剂可为本领域常规的洗脱剂,优选石油醚和乙酸乙酯。
在某一优选技术方案中,当所述述氮杂环卡宾配体为非手性氮杂环卡宾配体为时,所述如式I所示的环丙烷类化合物的制备方法,得到产物I-A1和产物I-A2;其中,所述产物I-A1与所述产物I-A2的摩尔比值为1:1;
在某一优选技术方案中,当所述述氮杂环卡宾配体为手性氮杂环卡宾配体为时,所述如式I所示的环丙烷类化合物的制备方法,得到产物I-A1和产物I-A2;其中,所述产物I-A1与所述产物I-A2的摩尔比值大于1;
在某一优选技术方案中,所述如式I所示的环丙烷类化合物的制备方法,还可包括以下步骤:步骤一:将所述的碱性试剂、所述氮杂环卡宾配体、所述钯催化剂、所述化合物B以及所述有机溶剂进行混合得到混合溶液;步骤二:将所述化合物A在步骤一得到的混合溶液中进行反应,得到如式I所示的环丙烷类化合物,即可。
本发明中,如式I所示的环丙烷类化合物的制备方法,还包括以下步骤:在卤化银作用下,将化合物C和碱性试剂在有机溶剂中进行如下反应,得到所述化合物A,即可;
其中,R1、R2和M+定义均如前所述。
所述碱性试剂可为本领域该类反应的常规用碱性试剂,优选为碱金属盐。所述碱金属盐可为钠/液氨、氨基钠、二异丙基氨基锂、氢钠、三苯基甲基钠、叔丁醇钠、乙醇钠、叔丁醇钾或六甲基二硅基胺基锂中的一种或多种;更优选六甲基二硅基胺基锂。
所述卤化银可为溴化银、氯化银和碘化银中一种或多种,优选溴化银。
所述有机溶剂如上所述。
所述碱性试剂与所述化合物C的摩尔比值,可为1~5;优选2~4,例如2。
所述卤化银与所述化合物C的摩尔比值,可为0.1~0.5,优选0.125~0.25,例如0.125,又例如0.25。
所述如式I所示的环丙烷类化合物的制备方法中所述化合物A,可不经过后处理直接应用于所述的化合物I的制备。
本发明还提供了一种如式A所示化合物:
其中,R1、R2和M+定义均如前所述。
本发明还提供了一种所述如式I所示的环丙烷类化合物,在制备如式D所示的伯胺类化合物中的应用,
所述应用,优选包括所述如D所示的伯胺类化合物的制备方法,其包括以下步骤:在还原剂作用下,将化合物I在有机溶剂中进行如下式的还原反应,得到化合物D,即可,
所述的还原反应可为本领域此类反应的常规反应。本发明优选以下条件。
所述还原剂可为本领域此类反应常规还原剂。优选金属盐还原剂。所述金属还原剂可为LiAlH4、DIBAL-H或NaBH4。优选LiAlH4。
所述有机溶剂可为本领域此类反应常规较溶剂。优选芳烃类溶剂、醚类溶剂和烷烃类溶剂中的一种或多种。所述的芳烃类溶剂优选为甲苯。所述的醚类溶剂优选四氢呋喃、乙二醇二甲醚、乙醚或二氧六环中的一种或多种;所述的烷烃类溶剂优选正己烷。
所述还原反应的反应温度可为-10~50℃,优选0~50℃。
所述还原剂与所述化合物I的摩尔比优选为1:1~1:2,例如1:1。
所述还原反应的反应的进程可以采用本领域的常规监测方法(如TLC、HPLC或NMR)进行监测,一般以化合物I消失或不反应为反应终点。所述还原反应的时间可为1h~20h,优选12h。
将上述如式I所示的环丙烷类化合物用于制备上述如D所示的伯胺类化合物,其收率可达96%,纯度可达95%。
本发明还提供了一种所述如式I所示的环丙烷类化合物,在制备如式E所示的酮类化合物的应用,
其中,R4为C6-14芳基或C1-6烷基,X为卤素。
所述应用,优选包括酮类化合物E的制备方法,其包括以下步骤:在格氏试剂的作用下,将化合物I在有机溶剂中进行如下式的加成反应,得到化合物E,即可,
其中,R4为C6-14芳基或C1-6烷基,X为卤素。
所述加成反应可为本领域此类反应常规反应,优选以下条件:
所述有机溶剂可为本领域此类反应常规有机溶剂。优选卤代烷烃类溶剂醚类溶剂或芳烃类溶剂中的一种或多种。所述卤代烷烃类溶剂可为二氯甲烷和/或氯仿。所述醚类溶剂可为四氢呋喃、二氧六环、乙醚或乙二醇二甲醚中的一种或多种,优选乙醚。所述的芳烃类溶剂优选甲苯。
所述的格氏试剂为本领域此类反应的常规格式试剂。
所述格氏试剂与所述的化合物I摩尔的比值可为1~3,例如1.1。
所述加成反应的反应温度可为0~100℃,优选60~90℃,例如80℃。
所述加成反应的反应进程可以采用本领域中的常规监测方法(如TLC、HPLC或NMR)进行监测,一般以化合物I消失时为反应终点。所述的反应的时间可为1h~20h,优选5h~15h,更优选12h。
将上述如式I所示的环丙烷类化合物用于制备上述如式E所示的酮类化合物,其收率可达75%,纯度可达95%。
本发明还提供了一种所述如式I所示的环丙烷类化合物,在制备如式F所示的环内酰胺类化合物的应用,
所述应用,优选还包括所述化合物F的制备方法,其包括以下步骤:在无机酸作用下,所述化合物I在溶剂中进行如下反应,得到化合物F,即可,
所述的无机酸为本领域中常规无机酸。本发明优选盐酸、硫酸和乙酸一种或多种。
所述反应的反应温度可为25~150℃,优选为60~150℃,例如110℃。
所述反应的反应进程可以采用本领域中的常规监测方法(如TLC、HPLC或NMR)进行监测,一般以化合物II消失时为反应终点。所述反应时的间可为1h~20h,优选5h~15h,例如12h。
将上述如式I所示的环丙烷类化合物用于制备上述如F所示的环内酰胺类化合物,其收率可达52%,纯度可达95%。
本发明中,当取代基的取代位置在“芳基与其它基团连接位点”的邻位和/或者对位时,“芳基与其它基团连接位点”中的芳基为苯基。
本发明中,“C1-10烷基”未作限定时,均包括直链和支链的C1-10烷基烷基。
本发明中,i-Propanol为异丙醇。
本发明中,室温为10~30℃。
在不违背本领域常识的基础上,上述各优选条件,可任意组合,即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
本发明的积极进步效果在于:本发明环丙烷类化合物的制备方法底物适用广,反应条件温和,后处理简单,环境友好,适合于工业化生产。采用本发明的制备方法能够简单、高效的制备得到多种类型的环丙烷类化合物。
附图说明
图1为实施例48中如式1所示的化合物的单晶的X-射线单晶衍射图。
具体实施方式
下面通过实施例的方式进一步说明本发明,但并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,按照常规方法和条件,或按照商品说明书选择。
实施例1
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(其结构式是系统命名为1,3-bis(2,6-dibenzhydryl-4-methylphenyl)-1H-imidazol-3-ium chloride,cas 1218778-19-8)(9.5mg,0.010mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物和产物二者比例为1:1,总收率76%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.27-7.23(m,2H),7.17-7.14(m,1H),7.08-7.06(m,2H),2.12-2.03(m,3H),1.75-1.73(m,3H),1.67-1.57(m,2H),1.45-1.39(m,2H),1.24-1.17(m,2H),1.11-1.06(m,1H),1.01-0.95(m,1H);13C NMR(101MHz,CDCl3):δ141.8,128.4,126.1,125.9,121.5,41.8,36.0,35.8,30.2,25.3,23.1(2C),19.8,11.9;IR(Neat):3063,3028,2932,2857,2233,2210,1605,1499,1450,752,697cm-1;MS(EI)m/z(rel):225(M+,12),180(5),117(100),104(7),91(11),73(12),53(1);HRMS(EI):calcd for C16H19N:225.1517,found:225.1524。
实施例2
氩气条件下,将(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物和产物二者比例为1:1,总收率83%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.29-7.25(m,2H),7.20-7.16(m,1H),7.10-7.08(m,2H),2.21-2.16(m,2H),2.12-2.07(m,1H),1.90-1.79(m,6H),1.24-1.17(m,2H),1.07-1.02(m,1H);13C NMR(101MHz,CDCl3):δ141.6,128.4,126.0,125.9,123.4,45.2,38.1(2C),28.4,24.3(2C),20.8,12.8;IR(Neat):3027,3003,2962,2874,2232,1605,1498,1453,1030,754,697cm-1;MS(EI)m/z(rel):211(M+,12),184(5),141(7),117(100),104(13),91(12),77(3),51(2);HRMS(EI):calcd for C15H17N:211.1361,found:211.1365。
实施例3
氩气条件下,将(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率73%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.29-7.25(m,2H),7.20-7.16(m,1H),7.10-7.08(m,2H),2.20-2.10(m,3H),1.76-1.49(m,10H),1.25-1.15(m,2H),1.05-1.00(m,1H);13C NMR(101MHz,CDCl3):δ141.8,128.4,126.0,125.9,122.3,44.8,38.8,38.6,31.2,27.9(2C),23.7,23.6,20.1,12.8;IR(Neat):3063,3027,2927,2857,2231,1735,1604,1497,1460,1255,1155,1034,838,751,696cm-1;MS(EI)m/z(rel):239(M+,3),154(2),122(6),117(100),115(18),104(13),91(17),77(5),57(38),41(13);HRMS(EI):calcd for C17H21N:239.1674,found:239.1686.
实施例4
氩气条件下,将(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率70%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.28-7.24(m,2H),7.19-7.15(m,1H),7.08-7.06(m,2H),4.00-3.94(m,2H),3.70(dt,J=12.0,2.0HZ,2H),2.16-2.11(m,1H),1.97-1.91(m,2H),1.82-1.74(m,2H),1.25-1.20(m,1H),1.17-1.12(m,1H),1.06-1.01(m,1H);13C NMR(101MHz,CDCl3):δ142.6,130.0,127.5,127.4,121.9,66.1,40.9,36.9,36.7,31.1,21.0,13.0;IR(Neat):3063,2957,2925,2852,2233,1736,1604,1498,1465,1443,1243,1143,1103,1032,835,757,697cm-1;MS(EI)m/z(rel):227(M+,8),141(4),117(100),104(7),91(21),77(5),57(9),41(3);HRMS(EI):calcd for C15H17NO:227.1310,found:227.1307.
实施例5
氩气条件下,将(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率74%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.29-7.25(m,2H),7.20-7.16(m,1H),7.08-7.06(m,2H),4.14-4.09(m,2H),3.04(br,2H),2.17-2.12(m,1H),2.03-1.98(m,2H),1.68-1.57(m,2H),1.46(s,9H),1.27-1.21(m,1H),1.14-1.09(m,1H),1.07-1.02(m,1H);13C NMR(101MHz,CDCl3):δ154.4,141.1,128.5,126.1(2C),120.2,80.1,40.7,34.8,29.3,28.4,19.8,11.8;IR(Neat):3005,2975,2864,2234,1691,1605,1421,1278,1159,863,760,697cm-1;MS(EI)m/z(rel):326(M+,2),270(45),253(32),226(100),135(50),117(56),94(24),57(77),51(3);HRMS(ESI):calcd for C20H26N2NaO2[M+Na]+:349.1886,found:349.1887.
实施例6
氩气条件下,将(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(0.76mg,0.002),IPr*·HCl(3.8mg,0.004mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率64%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.30-7.26(m,2H),7.20-7.16(m,1H),7.11-7.09(m,2H),2.12-2.07(m,1H),1.48(s,3H),1.47(s,3H),1.21-1.11(m,2H),1.06-1.01(m,1H);13C NMR(101MHz,CDCl3):δ141.6,128.4,126.0(2C),122.9,34.9,30.8,26.7(2C),20.6,12.6;IR(Neat):3029,2978,2935,2236,1605,1498,1466,753,697cm-1;MS(EI)m/z(rel):185(M+,10),143(13),117(100),104(8),91(13),77(6),65(3),51(3);HRMS(EI):calcd forC13H15N:185.1204,found:185.1201.
实施例7
氩气条件下,将(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率77%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.30-7.26(m,2H),7.20-7.16(m,1H),7.09-7.06(m,2H),2.08-2.04(m,1H),1.86-1.66(m,4H),1.22-1.17(m,1H),1.13(t,J=7.6Hz,3H),1.09-1.04(m,4H),0.99-0.94(m,1H);13C NMR(101MHz,CDCl3):δ141.7,128.5,125.9,125.8,121.0,45.3,31.4,31.3,28.1,20.3,12.5,9.6,9.4;IR(Neat):3065,3028,2970,2938,2881,2232,1739,1605,1497,1460,1383,1156,1113,1027,884,751,697cm-1;MS(EI)m/z(rel):213(M+,3),157(4),129(5),117(100),104(13),91(16),77(5),51(3));HRMS(EI):calcd forC15H19N:213.1517,found:213.1521.
实施例8
氩气条件下,将(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率48%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):(taken as a mixture of diastereomers):δ7.30-7.25(m,2.45H),7.20-7.16(m,1.26H),7.10-7.05(m,2.44H),2.15-2.10(m,1H),2.03-2.00(m,0.24H),1.95-1.91(m,2.42H),1.86-1.76(m,2.42H),1.71-1.64(m,1.29H),1.53-1.47(m,1.33H),1.42(s,3H),1.30-1.13(m,8.65H),1.12-1.04(m,2.52H),1.01-0.97(m,1H);13CNMR(101MHz,CDCl3):(taken as a mixture of diastereomers):δ141.9,141.5,128.4(2C),125.9(2C),125.8,121.6,121.5,46.6(2C),44.3,44.0,28.6,28.5(2C),28.4,28.3,27.9,26.3(3C),26.1,26.0,25.9,24.4,22.8(2C),22.1,19.6,14.5,11.8;IR(Neat):3064,2927,2854,2232,1737,1604,1497,1450,1376,1277,1256,933,889,843,753,697cm-1;MS(EI)m/z(rel):253(M+,3),170(13),156(9),128(6),117(100),104(18),91(16),77(5),55(18),41(10);HRMS(EI):calcd for C18H23N:253.1830,found:253.1826.
实施例9
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(6.08mg,0.008mmol),IPr*·HCl(18.0mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M inTHF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率64%,1HNMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.04-7.00(m,2H),6.83-6.79(m,2H),3.78(s,3H),2.10-2.03(m,3H),1.77-1.74(m,3H),1.68-1.58(m,2H),1.45(m,2H),1.25-1.19(m,1H),1.17-1.12(m,1H),1.05-1.00(m,1H),0.95-0.90(m,1H);13C NMR(101MHz,CDCl3):δ157.9,133.8,127.3,121.6,113.8,55.3,41.7,36.0,35.8,29.7,25.3,23.1,23.0,19.1,11.4;IR(Neat):3078,2923,2854,2231,1608,1514,1456,1444,1246,1175,1028,828,815,697cm-1;MS(EI)m/z(rel):255(M+,5),225(13),147(23),117(100),104(7),91(12),57(4);HRMS(EI):calcd for C17H21NO:255.1623,found:225.1621.
实施例10
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率65%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.24-7.21(m,2H),7.02-6.99(m,2H),2.10-2.03(m,3H),1.78-1.74(m,3H),1.68-1.61(m,2H),1.47-1.37(m,2H),1.25-1.19(m,2H),1.08-1.03(m,1H),0.99-0.95(m,1H);13C NMR(101MHz,CDCl3):δ140.3,131.5,128.5,127.4,121.3,41.7,36.0,35.7,30.4,25.2,23.1,23.0,19.3,11.9;IR(Neat):3010,2923,2855,2235,1493,1450,1085,1011,891,811,646cm-1;MS(EI)m/z(rel):259(M+,12),151(100),147(13),115(24),91(3),57(4);HRMS(EI):calcd for C16H18NCl:259.1128,found:259.1129.
实施例11
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率69%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.17-7.10(m,3H),6.95-6.91(m,1H),2.45(s,3H),2.17-2.07(m,3H),1.82-1.77(m,3H),1.72-1.60(m,2H),1.55-1.41(m,2H),1.30-1.15(m,3H),0.94-0.87(m,1H);13C NMR(101MHz,CDCl3):δ139.3,137.5,129.8,126.1,125.9,125.3,121.6,41.6,36.6,35.8,28.7,25.3,23.2,23.1,19.9,17.8,10.7;IR(Neat):3067,2932,2857,2232,1739,1604,1494,1450,1265,1162,1113,891,757,732cm-1;MS(EI)m/z(rel):239(M+,7),131(100),115(13),105(6),91(14),77(5),55(2),41(3);HRMS(EI):calcd forC17H21N:239.1674,found:239.1678.
实施例12
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率49%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.18-7.14(t,J=7.6Hz,1H),7.00-6.98(d,J=7.6Hz,1H),6.90-6.88(m,2H),2.32(s,3H),2.11-2.05(m,3H),1.79-1.74(m,3H),1.69-1.59(m,2H),1.50-1.39(m,2H),1.26-1.16(m,2H),1.12-1.07(m,1H),1.02-0.97(m,1H);13C NMR(101MHz,CDCl3):δ141.8,138.0,128.3,126.9,126.7,123.1,121.5,41.8,36.0,35.8,30.1,25.3,23.1(2C),21.4,19.8,11.9;IR(Neat):3009,2931,2857,2233,1738,1607,1491,1449,1272,1038,904,780,698cm-1;MS(EI)m/z(rel):239(M+,7),131(100),115(11),105(6),91(12),77(4),41(3);HRMS(EI):calcd for C17H21N:239.1674,found:239.1667.
实施例13
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率99%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.09-6.98(m,4H),2.31(s,3H),2.11-2.04(m,3H),1.77-1.75(m,3H),1.65-1.59(m,2H),1.47-1.38(m,2H),1.26-1.15(m,2H),1.09-1.04(m,1H),0.99-0.94(m,1H);13C NMR(101MHz,CDCl3):δ138.8,135.5,129.1,126.0,121.6,41.8,36.0,35.8,30.0,25.3,23.1(2C),21.0,19.5,11.7;IR(Neat):3077,3003,2928,2854,2236,1740,1514,1450,1260,1090,942,806,712cm-1;MS(EI)m/z(rel):239(M+,7),131(100),115(11),105(6),91(12),77(4),41(4);HRMS(EI):calcd for C17H21N:239.1674,found:239.1677.
实施例14
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物和二者比例为1:1,总收率54%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.15-7.01(m,4H),2.87(hept,J=6.8Hz,1H),2.11-2.05(m,3H),1.77-1.75(m,3H),1.68-1.60(m,2H),1.47-1.39(m,2H),1.24(d,J=6.8Hz,6H),1.20-1.15(m,2H),1.11-1.07(m,1H),0.99-0.94(m,1H);13C NMR(101MHz,CDCl3):δ146.5,139.2,126.4,126.1,121.6,41.8,36.0,35.9,33.7,29.9,25.3,24.0,23.1(2C),19.5,11.8;IR(Neat):3070,2934,2858,2229,1613,1516,1445,1106,1047,926,890,820cm-1;MS(EI)m/z(rel):267(M+,9),224(5),197(4),159(25),131(14),117(100),91(14),77(7),57(39),43(40);HRMS(EI):calcd for C19H25N:267.1987,found:267.1989.
实施例15
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率54%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.81-7.75(m,3H),7.54(s,1H),7.48-7.40(m,2H),7.22(d,J=10.8Hz,1H),2.32-2.27(m,1H),2.13(t,J=13.6Hz,2H),1.79-1.76(m,3H),1.71-1.59(m,2H),1.51-1.44(m,2H),1.32-1.12(m,4H);13C NMR(101MHz,CDCl3):δ139.3,133.4,132.0,128.1,127.6,127.3,126.2,125.2,124.9,124.2,121.5,41.9,36.0,35.9,30.4,25.3,23.1,23.0,20.1,11.9;IR(Neat):3073,2936,2854,2237,1759,1729,1507,1401,1260,1084,906,849,812,744cm-1;MS(EI)m/z(rel):275(M+,13),201(6),167(100),152(16),117(15),107(8),91(6),77(7),41(6);HRMS(EI):calcd for C20H21N:275.1674,found:275.1673.
实施例16
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.05mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率99%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.23-7.22(m,1H),6.27-6.25(m,1H),5.98(d,J=3.2Hz,1H),2.13-2.02(m,3H),1.78-1.74(m,3H),1.67-1.57(m,2H),1.49-1.38(m,2H),1.26-1.19(m,2H),1.17-1.11(m,1H),1.07-1.03(m,1H);13C NMR(101MHz,CDCl3):δ155.2,140.6,121.2,110.3,104.1,41.4,35.8,35.7,27.8,25.3,23.0,13.2,10.2;IR(Neat):3468,3118,2933,2858,2234,1700,1601,1449,1400,1184,1148,1014,919,798,732,700cm-1;MS(EI)m/z(rel):215(M+,6),107(100),94(11),79(19),53(5),41(4);HRMS(EI):calcd forC14H17NO:215.1310,found:215.1315.
实施例17
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物和二者比例为1:1,总收率82%,1HNMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ2.09(t,J=6.8Hz,2H),2.04(d,J=13.2Hz,1H),1.95(d,J=13.2Hz,1H),1.75-1.72(m,3H),1.60-1.54(m,2H),1.48-1.31(m,7H),1.24-1.15(m,1H),1.09-1.05(m,1H),0.97-0.92(m,1H),0.89(t,J=6.8Hz,3H),0.85-0.81(m,1H);13CNMR(101MHz,CDCl3):δ120.8,81.2,76.7,41.2,35.7,35.6,31.0,29.0,25.2,23.0,21.9,18.4,13.6,11.8,4.0;IR(Neat):3008,2932,2859,2233,1737,1450,1253,1095,931,844,696cm-1;MS(EI)m/z(rel):229(M+,7),200(6),180(22),166(13),121(20),113(14),109(18),93(30),79(51),73(100),67(27),57(36),45(9);HRMS(EI):calcd for C16H23N:229.1830,found:229.1838.
实施例18
氩气条件下,将(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M inTHF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物和二者比例为1:1,总收率76%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ2.10-2.06(m,4H),1.80-1.70(m,6H),1.45-1.29(m,5H),1.18-1.13(m,1H),0.94-0.82(m,5H);13C NMR(101MHz,CDCl3):δ122.8,80.9,77.0,44.6,38.1,37.9,31.0,27.2,24.3(2C),21.9,18.4,13.6,12.7,5.1;IR(Neat):3009,2958,2932,2872,2233,1716,1620,1452,1364,1256,1043,958,909,750cm-1;MS(EI)m/z(rel):215(M+,16),186(12),172(15),121(23),108(26),93(74),79(100),67(28),55(24),51(10);HRMS(EI):calcd for C15H21N:215.1674,found:215.1677.
实施例19
氩气条件下,将(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M inTHF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率81%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ2.16-2.03(m,4H),1.78-1.65(m,8H),1.56-1.32(m,7H),1.17-1.12(m,1H),0.99-0.94(m,1H),0.90(t,J=7.2Hz,3H),0.88-0.85(m,1H);13C NMR(101MHz,CDCl3):δ121.6,81.2,76.9,44.2,38.5(2C),31.0,30.0,27.8,23.6,23.5,21.9,18.4,13.6,12.6,5.0;IR(Neat):3008,2928,2859,2232,1718,1460,1257,1075,1043,887,843,803,749cm-1;MS(EI)m/z(rel):243(M+,11),214(11),136(16),121(39),93(70),79(100),67(36),55(36);HRMS(EI):calcd for C17H25N:243.1987,found:243.1993.
实施例20
氩气条件下,将(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M inTHF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率70%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ3.96-3.93(m,2H),3.64(tt,J=12.0,2.4Hz,2H),2.08(td,J=7.2,1.2Hz,2H),1.93-1.89(m,1H),1.84-1.67(m,3H),1.44-1.29(m,5H),1.14-1.09(m,1H),0.99-0.94(m,1H),0.89-0.84(m,4H);13C NMR(101MHz,CDCl3):δ119.8,80.6,77.2,64.6(2C),39.1,35.3,35.2,30.9,28.5,21.9,18.4,13.6,11.6,4.0;IR(Neat):3009,2956,2928,2855,2237,1739,1465,1389,1243,1192,1143,1104,943,845,750cm-1;MS(EI)m/z(rel):231(M+,18),202(7),174(19),160(18),146(23),134(24),119(26),108(23),93(53),79(100),67(33),55(35),51(12);HRMS(EI):calcd for C15H21NO:231.1623,found:231.1629.
实施例21
氩气条件下,将(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M inTHF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率68%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ4.11(br,2H),2.99(br,2H),2.09(t,J=5.6Hz,2H),1.99-1.86(m,2H),1.66-1.51(m,2H),1.45-1.34(m,14H),1.10-1.05(m,1H),1.00-0.95(m,1H),0.90-0.86(m,4H);13C NMR(101MHz,CDCl3):δ154.4,119.5,80.5,80.1,77.2,40.1,34.7,30.9,28.4,28.2,21.9,18.4,13.6,11.7,4.2;IR(Neat):3007,2931,2864,2236,1694,1420,1366,1278,1248,1159,1108,1022,862,769cm-1;MS(EI)m/z(rel):330(M+,1),274(28),257(9),230(14),187(35),94(21),57(100),51(3);HRMS(EI):calcd forC20H30N2O2:330.2307,found:330.2298.
实施例22
氩气条件下,将(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M inTHF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率72%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ2.10(t,J=6.8Hz,2H),1.44-1.33(m,11H),1.11-1.06(m,1H),0.94-0.83(m,5H);13C NMR(101MHz,CDCl3):δ122.3,80.9,77.0,34.4,31.0,29.7,26.5(2C),21.9,18.4,13.6,12.5,4.8;IR(Neat):3084,2959,2933,2872,2237,1717,1620,1464,1368,1328,1254,1188,1101,1076,1044,920,885,803,751cm-1;MS(EI)m/z(rel):189(M+,17),174(30),151(16),121(26),105(20).91(57),79(100),67(29),55(30),51(12);HRMS(EI):calcd for C13H19N:189.1517,found:189.1514.
实施例23
氩气条件下,将(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率76%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ2.10-2.07(m,2H),1.83-1.60(m,4H),1.45-1.30(m,5H),1.10(t,J=7.2Hz,3H),1.04(t,J=7.2Hz,3H),0.94-0.82(m,6H);13C NMR(101MHz,CDCl3):δ120.3,81.0,76.9,44.6,31.2,31.1,31.0,26.5,21.9,18.4,13.6,11.9,9.4,9.2,4.7;IR(Neat):3084,2965,2933,2866,2233,1718,1620,1461,1383,1258,1103,1078,1045,903,886,786cm-1;MS(EI)m/z(rel):217(M+,6),188(16),174(13),121(32),105(14),93(66),79(100),67(27),55(29),51(8);HRMS(EI):calcd for C15H23N:217.1830,found:217.1826.
实施例24
氩气条件下,将(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率80%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):(taken as a mixture of diastereomers):δ2.11-1.68(m,10.16H),1.49-0.94(m,23.19H),0.91-0.87(m,4H),0.83-0.79(m,1.80H);13C NMR(101MHz,CDCl3):(taken as a mixture of diastereomers):δ121.0,120.8,81.2,80.9,77.1,76.8,46.5,46.4,43.6,43.4,31.0(2C),28.5,28.4(2C),28.2,27.3,27.2,26.3(3C),26.0,22.9,22.4,21.9(2C),18.4,14.2,13.6,11.1,6.8,3.9;IR(Neat):3084,2928,2856,2233,1451,1377,1255,1103,1044,928,891,839,798,750cm-1;MS(EI)m/z(rel):257(M+,11),242(7),228(22),214(24),200(9),174(21),160(15),150(27),132(72),121(47),107(24),93(90),79(100),67(35),55(75);HRMS(EI):calcd for C17H28N:257.2143,found:257.2148.
实施例25
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率77%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ2.10-2.06(m,3H),1.95(d,J=12.8Hz,1H),1.74-1.72(m,3H),1.60-1.53(m,2H),1.47-1.37(m,5H),1.34-1.29(m,4H),1.24-1.18(m,1H),1.09-1.04(m,1H),0.97-0.80(m,5H);13C NMR(101MHz,CDCl3):δ120.8,81.2,76.8,41.2,35.7,35.6,31.0,29.0,28.6,25.2,23.0,22.2,18.7,14.0,11.8,4.1;IR(Neat):3009,2931,2858,2233,1737,1451,1257,1093,1074,861,805,731cm-1;MS(EI)m/z(rel):243(M+,8),228(4),200(16),186(13),174(7),135(25),107(36),93(89),79(100),67(44),55(35);HRMS(EI):calcd for C17H25N:243.1987,found:243.1991.
实施例26
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率81%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ2.07-1.94(m,4H),1.75-1.72(m,4H),1.62-1.55(m,2H),1.49-1.31(m,3H),1.26-1.19(m,1H),1.10-1.06(m,1H),1.00-0.93(m,7H),0.87-0.82(m,1H);13C NMR(101MHz,CDCl3):δ120.9,82.1,75.6,41.2,35.7,35.6,29.1,28.2,27.9,25.2,23.0,21.9,11.8,4.1;IR(Neat):3008,2933,2861,2233,1737,1450,1278,1254,1105,1073,960,886,861,844,809,751cm-1;MS(EI)m/z(rel):229(M+,18),214(15),186(15),160(11),121(100),109(22),93(69),79(53),73(30),67(19),57(39),53(11);HRMS(EI):calcd for C16H23N:229.1830,found:229.1835.
实施例27
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率80%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ2.50-2.43(m,1H),2.03(d,J=13.2Hz,1H),1.94(d,J=13.2Hz,1H),1.74-1.72(m,3H),1.63-1.52(m,2H),1.49-1.33(m,3H),1.23-1.14(m,1H),1.11-1.02(m,7H),0.97-0.92(m,1H),0.84-0.80(m,1H);13C NMR(101MHz,CDCl3):δ120.9,82.3,80.4,41.2,35.7,35.6,29.1,25.2,23.2,23.0,20.4,11.9,4.0;IR(Neat):2934,2860,2237,1710,1450,1359,1260,1090,1069,1000,852,809cm-1;MS(EI)m/z(rel):215(M+,16),200(14),172(16),156(13),146(17),131(20),121(25),105(100),95(79),91(74),79(98),65(34),55(34);HRMS(EI):calcd for C15H21N:215.1674,found:215.1666.
实施例28
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率75%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ2.04(d,J=12.8Hz,1H),1.94(d,J=12.8Hz,1H),1.75-1.73(m,3H),1.63-1.51(m,2H),1.49-1.34(m,3H),1.25-1.17(m,1H),1.15(s,9H),1.08-1.03(m,1H),0.97-0.92(m,1H),0.83-0.78(m,1H);13C NMR(101MHz,CDCl3):δ120.9,85.1,79.6,41.2,35.7,35.6,31.2,29.1,27.2,25.2,23.0,12.0,4.0;IR(Neat):2926,2857,2231,1739,1451,1363,1260,1088,1020,926,800,731,700cm-1;MS(EI)m/z(rel):229(M+,16),214(19),121(32),105(36),93(100),79(34),55(10);HRMS(EI):calcd for C16H23N:229.1830,found:229.1828.
实施例29
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率71%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ3.61(t,J=6.4Hz,2H),2.30(td,J=6.8,1.6Hz,2H),2.05-2.02(m,1H),1.99-1.86(m,3H),1.75-1.73(m,3H),1.66-1.53(m,2H),1.48-1.33(m,3H),1.27-1.15(m,1H),1.11-1.06(m,1H),0.99-0.94(m,1H),0.86-0.82(m,1H);13C NMR(101MHz,CDCl3):δ120.8,82.4,74.6,43.7,41.2,35.7,35.6,31.6,29.0,25.2,23.0,16.2,11.8,3.9;IR(Neat):3007,2932,2858,2234,1736,1449,1288,1154,1011,884,860,724,652cm-1;MS(EI)m/z(rel):249(M+,8),214(11),141(100),122(22),105(39),91(29),77(40),65(15),57(11);HRMS(EI):calcd for C15H20NCl:249.1284,found:249.1289.
实施例30
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(3.8mg,0.005mmol),IPr*·HCl(18.0mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率60%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.28(t,J=7.6Hz,2H),6.98-6.91(m,3H),4.61(s,2H),2.01(d,J=13.2Hz,1H),1.93(d,J=13.2Hz,1H),1.74-1.71(m,3H),1.61-1.55(m,1H),1.52-1.33(m,4H),1.23-1.13(m,2H),1.04-0.99(m,1H),0.94-0.90(m,1H);13C NMR(101MHz,CDCl3):δ157.7,129.4,121.3,120.6,114.8,89.1,71.3,56.4,41.2,35.7,35.6,29.2,25.2,22.9,12.0,3.9;IR(Neat):3009,2926,2857,2239,1599,1496,1453,1377,1230,1016,991,885,820,748,688cm-1;MS(EI)m/z(rel):279(M+,11),264(12),236(12),224(11),186(32),171(100),158(31),144(49),131(38),117(39),105(30),94(64),77(68),65(64),51(25);HRMS(EI):calcd for C19H21NO:279.1623,found:279.1630.
实施例31
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率59%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ5.85-5.80(m,1H),5.06-4.99(m,2H),2.31-2.19(m,4H),2.03(d,J=12.8Hz,1H),1.95(d,J=12.8Hz,1H),1.75-1.72(m,3H),1.63-1.53(m,2H),1.48-1.30(m,3H),1.24-1.18(m,1H),1.10-1.05(m,1H),0.98-0.93(m,1H),0.86-0.81(m,1H);13C NMR(101MHz,CDCl3):δ137.1,120.8,115.5,81.8,75.9,41.2,35.7,35.6,33.2,29.0,25.2,23.0,18.6,11.8,4.0;IR(Neat):3079,3006,2932,2858,2233,1641,1449,1261,994,913,861,826,626cm-1;MS(EI)m/z(rel):227(M+,5),198(6),184(7),170(7),158(7),144(7),130(8),119(82),105(17),91(100),79(24),67(18),53(9);HRMS(EI):calcdfor C16H21N:227.1674,found:227.1675.
实施例32
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.10mmol),四甲基乙二胺(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(0.38mg,0.001mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为1:1,总收率45%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.36-7.26(m,5H),2.11(d,J=13.2Hz,1H),2.00(d,J=13.2Hz,1H),1.81-1.75(m,3H),1.69-1.60(m,3H),1.54-1.39(m,2H),1.30-1.21(m,2H),1.16-1.10(m,1H),1.07-1.02(m,1H);13C NMR(101MHz,CDCl3):δ131.6,128.2,127.7,123.5,120.7,91.2,41.32,35.8,35.7,29.5,25.2,23.0,12.4,4.6;IR(Neat):3014,2930,2856,2230,1598,1491,1448,1253,943,913,844,755,691cm-1;MS(EI)m/z(rel):249(M+,8),193(6),180(7),159(10),141(40),126(13),111(12),97(18),83(24),73(100),57(40),45(16);HRMS(EI):calcd for C18H19N:249.1517,found:249.1511.
实施例33
氩气条件下,将环己基甲腈(0.4mmol),1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入1.2mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率62%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ2.04-1.91(m,2H),1.75-1.72(m,3H),1.64-1.54(m,2H),1.42-1.30(m,2H),1.28-1.14(m,1H),0.79-0.74(m,1H),0.67-0.62(m,1H),0.44-0.40(m,1H),-0.05(s,9H),-0.15--0.21(m,1H);13C NMR(101MHz,CDCl3):δ121.6,42.5,36.2,36.1,25.4,23.6,23.2,23.1,5.6,1.1,-2.6;IR(Neat):3062,2935.2859,2235,1738,1451,1249,1080,1019,891,835,751.692cm-1;MS(EI)m/z(rel):221(M+,2),179(31),151(16),122(74),107(50),100(38),93(28),73(100),59(20),45(12);HRMS(EI):calcd forC13H23NSi:221.1600,found:221.1602.
实施例34
氩气条件下,将(0.4mmol),1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入1.2mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(7.6mg,0.02mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率50%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ2.13-1.99(m,2H),1.69-1.47(m,10H),0.79-0.70(m,2H),0.46-0.41(m,1H),-0.05(s,9H),-0.12--0.20(m,1H);13C NMR(101MHz,CDCl3):δ122.4,45.4,39.0,38.9,27.9,27.8,24.6,23.6,6.4,2.1,-2.5;IR(Neat):3061,2930,2858,2231,1739,1459,1248,981,876,832,749,691,673cm-1;MS(EI)m/z(rel):235(M+,2),220(5),193(20),166(10),136(32),121(57),107(36),100(23),94(26),73(100),59(20),45(13);HRMS(EI):calcd for C14H25NSi:235.1756,found:221.1748.
实施例35
氩气条件下,将(0.4mmol),1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入1.6mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率51%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ1.81-1.59(m,4H),1.09-1.01(m,6H),0.75-0.71(m,1H),0.59-0.54(m,1H),0.46-0.42(m,1H),-0.05(s,9H),-0.19--0.25(m,1H);13C NMR(101MHz,CDCl3):δ121.2,45.8,31.3,30.9,20.9,9.4,9.1,6.4,1.1,-2.4;IR(Neat):3063,2955,2884,2232,1741,1249,1094,1039,1012,901,879,834,749,692cm-1;MS(EI)m/z(rel):209(M+,1),180(25),110(52),100(18),95(24),81(43),73(100),59(16),45(10);HRMS(EI):calcd for C12H23NSi:209.1600,found:209.1599.
实施例36
氩气条件下,将环己基甲腈(0.4mmol),溴化银(0.10mmol),1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入0.8mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),IPr*·HCl(9.5mg,0.01mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在室温下搅拌12h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为1:1,总收率59%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.30-7.27(m,2H),7.02-6.95(m,3H),3.89-3.87(m,1H),2.16(d,J=12.4Hz,1H),1.97(d,J=13.6Hz,1H),1.76-1.74(m,3H),1.67-1.58(m,2H),1.52-1.35(m,2H),1.30-1.19(m,2H),1.09-1.04(m,1H),0.99-0.97(m,1H);13C NMR(101MHz,CDCl3):δ158.2,129.4,121.3(2C),115.0,53.2,39.9,35.9,35.4,26.6,25.1,23.0,22.8,10.6;IR(Neat):3017,2941,2859,2227,1731,1599,1586,1483,1447,1243,1154,1092,1070,856,757,690cm-1;MS(EI)m/z(rel):241(M+,9),184(1),133(100),105(33),94(15),77(20),65(8),51(7);HRMS(EI):calcd for C16H19NO:241.1467,found:241.1477.
实施例37
氩气条件下,将环己基甲腈(1.0mmol),溴化锂(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入2.0mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),氮杂环卡宾配体(系统命名为1,3-bis(4-methyl-2-((S)-1-phenylethyl)-6-(1-phenylethyl)phenyl)-1H-imidazol-3-ium chloride)(7.0mg,0.010mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在-30℃搅拌48h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物 二者比例为61:39,总收率40%,1H NMR的纯度大于95%。
HPLC(Chiralpak AD-H,Hexane:i-Propanol=98:2,1mL/min,214nm):tminor=5.52min,tmajor=6.62min。[α]D 30=-105.7(1.0,CHCl3).;1H NMR(400MHz,CDCl3):δ7.29-7.25(m,2H),7.20-7.16(m,1H),7.10-7.08(m,2H),2.21-2.16(m,2H),2.12-2.07(m,1H),1.90-1.79(m,6H),1.24-1.17(m,2H),1.07-1.02(m,1H);13C NMR(101MHz,CDCl3):δ141.6,128.4,126.0,125.9,123.4,45.2,38.1(2C),28.4,24.3(2C),20.8,12.8;IR(Neat):3027,3003,2962,2874,2232,1605,1498,1453,1030,754,697cm-1;MS(EI)m/z(rel):211(M+,12),184(5),141(7),117(100),104(13),91(12),77(3),51(2);HRMS(EI):calcd for C15H17N:211.1361,found:211.1365.
实施例38
氩气条件下,将环己基甲腈(1.0mmol),溴化锂(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入2.0mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),氮杂环卡宾配体(系统命名为(4R,5R)-1,3-bis(2,6-diisopropylphenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-ium tetrafluoroborate)(6.3mg,0.010mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在-30℃搅拌48h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为77:23,总收率43%,1H NMR的纯度大于95%。
HPLC(Chiralpak AD-H,Hexane:i-Propanol=98:2,1mL/min,214nm):tminor=5.52min,tmajor=6.62min。[α]D 30=-105.7(1.0,CHCl3).;1H NMR(400MHz,CDCl3):δ7.29-7.25(m,2H),7.20-7.16(m,1H),7.10-7.08(m,2H),2.21-2.16(m,2H),2.12-2.07(m,1H),1.90-1.79(m,6H),1.24-1.17(m,2H),1.07-1.02(m,1H);13C NMR(101MHz,CDCl3):δ141.6,128.4,126.0,125.9,123.4,45.2,38.1(2C),28.4,24.3(2C),20.8,12.8;IR(Neat):3027,3003,2962,2874,2232,1605,1498,1453,1030,754,697cm-1;MS(EI)m/z(rel):211(M+,12),184(5),141(7),117(100),104(13),91(12),77(3),51(2);HRMS(EI):calcd for C15H17N:211.1361,found:211.1365.
实施例39
氩气条件下,将环己基甲腈(1.0mmol),溴化锂(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入2.0mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),氮杂环卡宾配体(系统命名为(4R,5R)-1,3-bis(2,6-diisopropyl-4-(naphthalen-1-yl)phenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-ium tetrafluoroborate)(8.8mg,0.010mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在-30℃搅拌48h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为85:15,总收率40%,1HNMR的纯度大于95%。
HPLC(Chiralpak AD-H,Hexane:i-Propanol=98:2,1mL/min,214nm):tminor=5.52min,tmajor=6.62min。[α]D 30=-105.7(1.0,CHCl3).;1H NMR(400MHz,CDCl3):δ7.29-7.25(m,2H),7.20-7.16(m,1H),7.10-7.08(m,2H),2.21-2.16(m,2H),2.12-2.07(m,1H),1.90-1.79(m,6H),1.24-1.17(m,2H),1.07-1.02(m,1H);13C NMR(101MHz,CDCl3):δ141.6,128.4,126.0,125.9,123.4,45.2,38.1(2C),28.4,24.3(2C),20.8,12.8;IR(Neat):3027,3003,2962,2874,2232,1605,1498,1453,1030,754,697cm-1;MS(EI)m/z(rel):211(M+,12),184(5),141(7),117(100),104(13),91(12),77(3),51(2);HRMS(EI):calcd for C15H17N:211.1361,found:211.1365.
实施例40
氩气条件下,将环己基甲腈(1.0mmol),溴化锂(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入2.0mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),氮杂环卡宾配体(系统命名为(4R,5R)-1,3-bis(4-(anthracen-9-yl)-2,6-diisopropylphenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-ium tetrafluoroborate)(9.8mg,0.010mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在-30℃搅拌48h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为94:6,总收率69%,1H NMR的纯度大于95%。
HPLC(Chiralpak AD-H,Hexane:i-Propanol=98:2,1mL/min,214nm):tminor=5.52min,tmajor=6.62min。[α]D 30=-105.7(1.0,CHCl3).;1H NMR(400MHz,CDCl3):δ7.29-7.25(m,2H),7.20-7.16(m,1H),7.10-7.08(m,2H),2.21-2.16(m,2H),2.12-2.07(m,1H),1.90-1.79(m,6H),1.24-1.17(m,2H),1.07-1.02(m,1H);13C NMR(101MHz,CDCl3):δ141.6,128.4,126.0,125.9,123.4,45.2,38.1(2C),28.4,24.3(2C),20.8,12.8;IR(Neat):3027,3003,2962,2874,2232,1605,1498,1453,1030,754,697cm-1;MS(EI)m/z(rel):211(M+,12),184(5),141(7),117(100),104(13),91(12),77(3),51(2);HRMS(EI):calcd for C15H17N:211.1361,found:211.1365.
实施例41
氩气条件下,将(1.0mmol),溴化锂(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入2.0mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),氮杂环卡宾配体(系统命名为(4R,5R)-1,3-bis(4-(anthracen-9-yl)-2,6-diisopropylphenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-iumtetrafluoroborate)(9.8mg,0.010mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在-30℃搅拌48h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为94.5:5.5,总收率90%,1H NMR的纯度大于95%。
HPLC(Chiralpak AD-H,Hexane:i-Propanol=98:2,1mL/min,214nm):tminor=5.78min,tmajor=6.40min.[α]D 29=-90.8(1.0,CHCl3);1H NMR(400MHz,CDCl3):δ7.29-7.25(m,2H),7.20-7.16(m,1H),7.10-7.08(m,2H),2.21-2.16(m,2H),2.12-2.07(m,1H),1.90-1.79(m,6H),1.24-1.17(m,2H),1.07-1.02(m,1H);13C NMR(101MHz,CDCl3):δ141.6,128.4,126.0,125.9,123.4,45.2,38.1(2C),28.4,24.3(2C),20.8,12.8;IR(Neat):3027,3003,2962,2874,2232,1605,1498,1453,1030,754,697cm-1;MS(EI)m/z(rel):211(M+,12),184(5),141(7),117(100),104(13),91(12),77(3),51(2);HRMS(EI):calcd for C15H17N:211.1361,found:211.1365.
实施例42
氩气条件下,将(1.0mmol),溴化锂(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入2.0mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),氮杂环卡宾配体(系统命名为(4R,5R)-1,3-bis(4-(anthracen-9-yl)-2,6-diisopropylphenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-iumtetrafluoroborate)(9.8mg,0.010mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在-30℃搅拌48h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为93:7,总收率61%,1HNMR的纯度大于95%。
HPLC(Chiralpak AD-H,Hexane:i-Propanol=98:2,1mL/min,214nm):tminor=5.83min,tmajor=7.06min.[α]D 30=-91.3(1.0,CHCl3);1H NMR(400MHz,CDCl3):δ7.29-7.25(m,2H),7.20-7.16(m,1H),7.10-7.08(m,2H),2.20-2.10(m,3H),1.76-1.49(m,10H),1.25-1.15(m,2H),1.05-1.00(m,1H);13C NMR(101MHz,CDCl3):δ141.8,128.4,126.0,125.9,122.3,44.8,38.8,38.6,31.2,27.9(2C),23.7,23.6,20.1,12.8;IR(Neat):3063,3027,2927,2857,2231,1735,1604,1497,1460,1255,1155,1034,838,751,696cm-1;MS(EI)m/z(rel):239(M+,3),154(2),122(6),117(100),115(18),104(13),91(17),77(5),57(38),41(13);HRMS(EI):calcd for C17H21N:239.1674,found:239.1686.
实施例43
氩气条件下,将(1.0mmol),溴化锂(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入2.0mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),氮杂环卡宾配体(系统命名为(4R,5R)-1,3-bis(4-(anthracen-9-yl)-2,6-diisopropylphenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-ium tetrafluoroborate)(9.8mg,0.010mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在-30℃搅拌48h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为94:6,总收率91%,1H NMR的纯度大于95%。
HPLC(Chiralpak IC,Hexane:i-Propanol=98:2,1mL/min,214nm):tmajor=14.76min,tminor=19.02min.[α]D 30=-95.2(1.0,CHCl3);1H NMR(400MHz,CDCl3):δ7.28-7.24(m,2H),7.19-7.15(m,1H),7.08-7.06(m,2H),4.00-3.94(m,2H),3.70(dt,J=12.0,2.0HZ,2H),2.16-2.11(m,1H),1.97-1.91(m,2H),1.82-1.74(m,2H),1.25-1.20(m,1H),1.17-1.12(m,1H),1.06-1.01(m,1H);13C NMR(101MHz,CDCl3):δ142.6,130.0,127.5,127.4,121.9,66.1,40.9,36.9,36.7,31.1,21.0,13.0;IR(Neat):3063,2957,2925,2852,2233,1736,1604,1498,1465,1443,1243,1143,1103,1032,835,757,697cm-1;MS(EI)m/z(rel):227(M+,8),141(4),117(100),104(7),91(21),77(5),57(9),41(3);HRMS(EI):calcd for C15H17NO:227.1310,found:227.1307.
实施例44
氩气条件下,将(1.0mmol),溴化锂(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入2.0mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),氮杂环卡宾配体(系统命名为(4R,5R)-1,3-bis(4-(anthracen-9-yl)-2,6-diisopropylphenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-ium tetrafluoroborate)(9.8mg,0.010mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在-30℃搅拌48h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为90:10,总收率72%,1HNMR的纯度大于95%。
HPLC(Chiralpak ID,Hexane:i-Propanol=99:1,1mL/min,214nm):tminor=28.62min,tmajor=30.71min.[α]D 30=-49.9(1.0,CHCl3);1H NMR(400MHz,CDCl3):δ7.29-7.25(m,2H),7.20-7.16(m,1H),7.08-7.06(m,2H),4.14-4.09(m,2H),3.04(br,2H),2.17-2.12(m,1H),2.03-1.98(m,2H),1.68-1.57(m,2H),1.46(s,9H),1.27-1.21(m,1H),1.14-1.09(m,1H),1.07-1.02(m,1H);13C NMR(101MHz,CDCl3):δ154.4,141.1,128.5,126.1(2C),120.2,80.1,40.7,34.8,29.3,28.4,19.8,11.8;IR(Neat):3005,2975,2864,2234,1691,1605,1421,1278,1159,863,760,697cm-1;MS(EI)m/z(rel):326(M+,2),270(45),253(32),226(100),135(50),117(56),94(24),57(77),51(3);HRMS(ESI):calcd for C20H26N2NaO2[M+Na]+:349.1886,found:349.1887.
实施例45
氩气条件下,将(1.0mmol),溴化锂(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入2.0mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),氮杂环卡宾配体(系统命名为(4R,5R)-1,3-bis(4-(anthracen-9-yl)-2,6-diisopropylphenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-iumtetrafluoroborate)(9.8mg,0.010mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入肉桂基碳酸叔丁酯(0.2mmol),反应在-30℃搅拌48h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物二者比例为96:4,总收率90%,1HNMR的纯度大于95%。
HPLC(Chiralpak OD-H,Hexane:i-Propanol=99:1,1mL/min,214nm):tmajor=7.11min,tminor=7.96min.[α]D 31=-84.8(1.0,CHCl3);1H NMR(400MHz,CDCl3):δ7.30-7.26(m,2H),7.20-7.16(m,1H),7.11-7.09(m,2H),2.12-2.07(m,1H),1.48(s,3H),1.47(s,3H),1.21-1.11(m,2H),1.06-1.01(m,1H);13C NMR(101MHz,CDCl3):δ141.6,128.4,126.0(2C),122.9,34.9,30.8,26.7(2C),20.6,12.6;IR(Neat):3029,2978,2935,2236,1605,1498,1466,753,697cm-1;MS(EI)m/z(rel):185(M+,10),143(13),117(100),104(8),91(13),77(6),65(3),51(3);HRMS(EI):calcd for C13H15N:185.1204,found:185.1201.
实施例46
氩气条件下,将(1.0mmol),溴化锂(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入2.0mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),氮杂环卡宾配体(系统命名为(4R,5R)-1,3-bis(4-(anthracen-9-yl)-2,6-diisopropylphenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-iumtetrafluoroborate)(9.8mg,0.010mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在-30℃搅拌48h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物比例为90:10,总收率52%,1HNMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.81-7.75(m,3H),7.51(s,1H),7.48-7.40(m,2H),7.22(d,J=7.6Hz,1H),2.28-2.24(m,1H),1.51(s 3H),1.50(s,3H),1.30-1.21(m,2H),1.19-1.15(m,1H);13C NMR(101MHz,CDCl3):δ139.0,133.4,132.1,128.1,127.6,127.3,126.2,125.3,124.8,124.2,123.0,35.0,31.0,26.8,26.7,20.9,12.6;IR(Neat):3058,2980,2922,2853,2235,2693,2630,1597,1505,1459,1367,1303,1251,1023,964,886,811,742,475cm-1;MS(EI)m/z(rel):235(M+,27),191(15),167(100),155(32),127(33),115(9),77(8),63(7),57(8),51(5);HRMS(EI):calcd for C17H17N:235.1361,found:235.1364;HPLC(Chiralpak IC,Hexane:i-Propanol=99.2:0.8,1mL/min,214nm):tmajor=12.57min,tminor=13.31min.[α]D 29=-50.5(1.0,CHCl3).
实施例47
氩气条件下,将(1.0mmol),溴化锂(0.10mmol)和1.0mL四氢呋喃加入到10mL的反应管中,0℃下加入2.0mL六甲基二硅基胺基锂(1.0M in THF),恢复室温搅拌30min,在另外一5mL的反应管中加入氯化烯丙基钯(II)二聚物(1.9mg,0.005mmol),氮杂环卡宾配体(系统命名为(4R,5R)-1,3-bis(4-(anthracen-9-yl)-2,6-diisopropylphenyl)-4,5-diphenyl-4,5-dihydro-1H-imidazol-3-iumtetrafluoroborate)(9.8mg,0.010mmol)和四氢呋喃(1.0mL),0℃下加入25μL叔丁醇钾(1.0M in THF),室温搅拌30min后,将两个反应管合并加入(0.2mmol),反应在-30℃搅拌48h后,加入0.5mL水淬灭,无水硫酸钠干燥。减压除去溶剂,柱层析分离得到产物比例为97:13,总收率71%,1H NMR的纯度大于95%。
87:13er;1H NMR(400MHz,CDCl3):δ7.23(s,1H),6.27(s,1H),6.00(d,J=2.8Hz,1H),2.10-2.05(m,1H),1.47(s,3H),1.45(s,3H),1.29-1.24(m,1H),1.13-1.05(m,2H);13CNMR(101MHz,CDCl3):δ154.9,140.7,122.6,110.3,104.2,34.6,28.5,26.6(2C),13.9,10.8;IR(Neat):2979,2930,2872,2237,1599,1510,1460,1372,1246,1183,1148,1013,966,798,731,597cm-1;MS(EI)m/z(rel):175(M+,51),117(7),107(100),94(24),79(75),77(57),65(12),63(5),57(1);HRMS(EI):calcd for C11H13N):175.0997,found:175.1003;HPLC(Chiralpak IE,Hexane:i-Propanol=99:1,1mL/min,214nm):tminor=10.49min,tmajor=10.99min.[α]D 29=-68.5(1.0,CHCl3).
实施例48
如式1所示的化合物的制备
步骤一:氩气条件下,将实施例45中HPLC保留时间为t=7.11min的产物(0.20mmol),1.0mL乙醚加入到10mL的反应管中,在0℃下加入LiAlH4(0.26mmol),恢复室温后,反应过夜。反应结束后,加入2.0mL饱和氯化铵水溶液淬灭,乙醚萃取(3×5mL),无水硫酸钠干燥,旋干溶剂得到产物,总收率96%。
步骤二:将步骤一得到的产物、1mL二氯甲烷和0.1mL三乙胺的混合溶液中,在0℃下加入对溴苯磺酰氯,恢复室温后,反应过夜。反应结束后,加入2.0mL水淬灭,乙醚萃取(3×5mL),无水硫酸钠干燥,旋干溶剂,得到产物即可。
如式1所示的化合物的单晶的制备
通过挥发法来培养单晶:取50mg步骤二得到的产物于10mL试管中,加入1mL二氯甲烷溶解后,再加入0.5mL正己烷。将试管置于装有15mL正己烷的锥形瓶中,将锥形瓶封口后放置在室温下结晶,即可。
检测方法X-射线单晶衍射
如式1所示的化合物的单晶参数
应用实施例1
氩气条件下,将(0.074mmol),1.0mL乙醚加入到10mL的反应管中,0℃下加入45μL苯基溴化镁(2.5M in Et2O),加热至80℃反应过夜。加入2.0mL饱和氯化铵水溶液淬灭,乙醚萃取(3×5mL),无水硫酸钠干燥,柱层析得到产物总收率75%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.70-7.68(m,2H),7.45-7.41(m,1H),7.36-7.32(m,2H),7.27-7.23(m,2H),7.17-7.14(m,1H),7.06-7.04(m,2H),2.24-2.18(m,2H),2.07-2.02(m,1H),1.60-1.57(m,3H),1.38-1.32(m,3H),1.25-1.24(m,3H),1.18-1.13(m,1H),107-1.02(m,1H);13C NMR(101MHz,CDCl3):δ208.2,142.5,139.5,130.7,128.3,127.9,127.7,125.8,125.7,50.5,33.5,33.2,31.9,25.9,23.3(2C),20.8,13.1;IR(Neat):3066,2927,2857,1667,1599,1496,1449,1324,1226,1159,1127,1068,984,931,781,749,693cm-1;MS(EI)m/z(rel):304(M+,10),243(5),200(34),131(14),117(100),105(82),91(73),77(43),67(11),55(16);HRMS(EI):calcd for C12H24O2:304.1827,found:304.1833.
应用实施例2
氩气条件下,将(0.20mmol),1.0mL乙醚加入到10mL的反应管中,0℃下加入LiAlH4(0.26mmol),恢复室温反应过夜。加入2.0mL饱和氯化铵水溶液淬灭,乙醚萃取(3×5mL),无水硫酸钠干燥,旋干溶剂得到产物总收率96%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.27-7.23(m,2H),7.16-7.12(m,1H),7.08-7.07(m,2H),2.57(s,2H),1.81-1.76(m,1H),1.30(br,2H),0.98-0.88(m,2H),0.83-0.79(m,7H);13C NMR(101MHz,CDCl3):δ143.8,128.3,125.8,125.3,54.4,34.5,31.8,23.0,22.8,18.2,11.0;IR(Neat):3064,3026,2954,1602,1496,1465,1363,1118,1070,1030,875,755,696cm-1;MS(EI)m/z(rel):189(M+,15),172(7),159(11),143(18),133(100),129(32),117(74),104(22),91(44),77(14),55(12);HRMS(EI):calcd for C13H19N:189.1517,found:189.1521.
应用实施例3
氩气条件下,将(0.10mmol),1.0mL水,1mL冰乙酸和1mL浓硫酸加入到25mL的反应管中,110下℃反应过夜。乙酸乙酯萃取(3×5mL),无水硫酸钠干燥,柱层析得到产物总收率52%,1H NMR的纯度大于95%。
1H NMR(400MHz,CDCl3):δ7.38-7.29(m,5H),5.76(br,1H),4.13(d,J=9.2Hz,1H),2.26-2.17(m,1H),1.92-1.85(m,1H),1.74-1.24(m,9H),0.97(d,J=7.2Hz,3H);13C NMR(101MHz,CDCl3):δ182.1,141.0,128.7,128.0,126.4,62.1,52.1,45.3,33.4,28.0,25.8,21.9,21.6,11.2;IR(Neat):3166,3065,3031,2922,2855,1675,1446,1339,1276,1233,1088,1063,841,802,697,664cm-1;MS(EI)m/z(rel):243(M+,38),228(17),202(10),188(100),175(22),160(13),117(11),106(25),91(15),81(15),77(11),67(9);HRMS(EI):calcd for C16H21NO:243.1623,found:243.1627。
Claims (23)
1.一种如式I所示的环丙烷类化合物的制备方法,其特征在于,其包括以下步骤:保护气体下,在碱性试剂、氮杂环卡宾配体与钯催化剂存在下,将化合物A与化合物B在有机溶剂中进行如下式反应,得到如式I所示的环丙烷类化合物,即可;
所述碱性试剂为六甲基二硅基胺基锂、六甲基二硅基胺基钠、二异丙基氨基锂、碱金属醇盐和碱金属碳酸盐一种或多种;
所述氮杂环卡宾配体为非手性氮杂环卡宾配体和/或手性氮杂环卡宾配体;
所述钯催化剂为金属钯和/或钯络合物;
其中,M+为K+、Na+或Li+;
R1和R2独立地为直链C1-10烷基、R1-1取代的直链C1-10烷基、支链C3-10烷基、R1-2取代的支链C3-10烷基、C3-10环烷基、R1-3取代的C3-10环烷基、C3-10杂环烷基、或、R1-4取代的C3-10杂环烷基;所述C3-10杂环烷基为杂原子选自N、O和S中一种或多种,杂原子数为1~4个的C3-10杂环烷基;所述R1-4取代的C3-10杂环烷基中的C3-10杂环烷基为杂原子选自N、O和S中一种或多种,杂原子数为1~4个的C3-10杂环烷基;
R1-1和R1-2独立地为卤素或羟基;R1-3和R1-4独立地为卤素、羟基、直链C1-10烷基、支链C3-10烷基或C1-10烷氧基;
或者,R1、R2及与它们相连的碳一起形成C3-10环烷基,R2-1取代的C3-10环烷基,C3-10杂环烷基,或,R2-2取代的C3-10杂环烷基;所述C3-10杂环烷基为杂原子选自N、O和S中一种或多种,杂原子数为1~4个的C3-10杂环烷基;所述R2-2取代的C3-10杂环烷基中的C3-10杂环烷基为杂原子选自N、O和S中一种或多种,杂原子数为1~4个的C3-10杂环烷基;
R3为C1-10烷氧基、C6-30芳基、R3-1取代的C6-30芳基、C3-30杂芳基、R3-2取代的C3-30杂芳基、C2-10炔基、R3-3取代的C2-10炔基、所述C3-30杂芳基为杂原子选自N、O和S中一种或多种,杂原子数为1~4个的C3-30杂芳基;所述R3-2取代的C3-30杂芳基中的C3-30杂芳基为杂原子选自N、O和S中一种或多种,杂原子数为1~4个的C3-30杂芳基;
R3-1和R3-2独立地为直链C1-10烷基、支链C3-10烷基、C1-10烷氧基、卤素、硝基或氰基;R3-3独立地为卤素、C2-10烯基、C1-10烷氧基、C6-30芳基、苯氧基或R3-3-1取代的C6-30芳基;R3-4独立地为C6-30芳基、或、R3-4-1取代的C6-30芳基;R3-5a、R3-5b和R3-5c独立地为直链C1-10烷基或支链C3-10烷基;
R3-3-1和R3-4-1独立地为直链C1-10烷基、支链C3-10烷基、C1-10烷氧基或卤素;
R1-1、R1-2、R1-3、R1-4、R2-1、R2-2、R3-1、R3-2、R3-3、R3-3-1和R3-4-1的个数独立地为1个或多个;当R1-1、R1-2、R1-3、R1-4、R2-1、R2-2、R3-1、R3-2、R3-3、R3-3-1和R3-4-1的个数独立地为多个时,R1-1、R1-2、R1-3、R1-4、R2-1、R2-2、R3-1、R3-2、R3-3、R3-3-1和R3-4-1独立地相同或不同。
和/或,R1和R2中,所述直链C1-10烷基为直链C1-6烷基;
和/或,R1和R2中,所述R1-1取代的直链C1-10烷基中的直链C1-10烷基为直链C1-6烷基;
和/或,R1和R2中,所述支链C3-10烷基和R1-2取代的支链C3-10烷基中的支链C3-10烷基独立地为支链C3-6烷基;
和/或,R1和R2中,所述C3-10环烷基为C4-10环烷基;
和/或,R1和R2中,所述R1-3取代的C3-10环烷基中的C3-10环烷基为C4-10环烷基;
和/或,R1和R2中,所述C3-10杂环烷基和所述R1-4取代的C3-10杂环烷基中的C3-10杂环烷基独立地为C4-10杂环烷基;
和/或,当R1、R2及与它们相连的碳一起形成C3-10环烷基时,所述C3-10环烷基为C4-10环烷基;
和/或,当R1、R2及与它们相连的碳一起形成C3-10杂环烷基时,所述C3-10杂环烷基为C4-10杂环烷基;
和/或,当R1、R2及与它们相连的碳一起形成C3-10杂环烷基时,所述C3-10杂环烷基中的杂原子为O和/或N;
和/或,当R1、R2及与它们相连的碳一起形成C3-10杂环烷基时,所述C3-10杂环烷基中的杂原子的个数为1个或2个;当所述杂原子为多个时,杂原子相同或不同;
和/或,当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2取代的C3-10杂环烷基中的C3-10杂环烷基为C4-10杂环烷基;
和/或,当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2取代的C3-10杂环烷基中的杂原子为O和/或N;
和/或,当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2取代的C3-10杂环烷基中的杂原子的个数为1或2;当所述杂原子为多个时,杂原子相同或不同;
和/或,当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2取代的C3-10杂环烷基中的C3-10杂环烷基为C4-10杂环烷基;
和/或,当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2的个数为1、2或3;当所述R2-2为多个时,所述R2-2相同或不同;
和/或,R3中,所述C6-30芳基和所述R3-1取代的C6-30芳基中的C6-30芳基独立地为C6-14芳基;
和/或,R3中,所述R3-1取代的C6-30芳基中的R3-1的个数为1、2或3;当所述R3-1为多个时,所述R3-1相同或不同;
和/或,R3中,所述R3-1取代的C6-30芳基中的R3-1取代位置为“芳基与其它基团连接位点”的邻位和/或对位;
和/或,R3-1中,所述直链C1-10烷基为直链C1-6烷基;
和/或,R3-1中,所述支链C3-10烷基为支链C3-6烷基;
和/或,R3-1中,所述C1-10烷氧基为C1-6烷氧基;
和/或,R3中,所述C3-30杂芳基为C6-14杂芳基;
和/或,R3中,所述C3-30杂芳基中的杂原子为N和/或O;
和/或,R3中,所述C3-30杂芳基中的杂原子的个数为1或2;当所述杂原子的个数为多个时,杂原子相同或不同;
和/或,R3中,所述C2-10炔基为C2-7炔基;
和/或,R3中,所述R3-3取代的C2-10炔基中C2-10炔基为C2-7炔基;
和/或,R3中,所述R3-3取代的C2-10炔基中的R3-3的个数为1、2或3;当所述R3-3的个数为多个时,R3-3相同或不同;
和/或,R3-3中,所述卤素为F、Cl、Br或I;
和/或,R3-3中,所述C2-10烯基为C2-6烯基;
和/或,R3-3中,所述C6-30芳基为C6-14芳基;
和/或,R3-4中,所述C6-30芳基为C6-14芳基;
和/或,R3-5a、R3-5b和R3-5c中,所述直链C1-10烷基独立地为直链C1-6烷基;
和/或,当R1为直链C1-10烷基、R1-1取代的直链C1-10烷基、支链C3-10烷基或R1-2取代的支链C3-10烷基时,R1和R2相同。
3.如权利要求2所述的制备方法,其特征在于,
R1和R2中,所述直链C1-10烷基为直链C1-3烷基;
和/或,R1和R2中,所述R1-1取代的直链C1-10烷基中的直链C1-10烷基为直链C1-3烷基;
和/或,R1和R2中,所述C3-10环烷基为C4-7环烷基;
和/或,R1和R2中,所述R1-3取代的C3-10环烷基中的C3-10环烷基为C4-7环烷基;
和/或,R1和R2中,所述C3-10杂环烷基和所述R1-4取代的C3-10杂环烷基中的C3-10杂环烷基独立地为C4-6杂环烷基;
和/或,当R1、R2及与它们相连的碳一起形成C3-10环烷基时,所述C3-10环烷基为C4-7环烷基;
和/或,当R1、R2及与它们相连的碳一起形成C3-10杂环烷基时,所述C3-10杂环烷基为C4-6杂环烷基;
和/或,当R1、R2及与它们相连的碳一起形成C3-10杂环烷基时,所述C3-10杂环烷基中的杂原子为O;
和/或,当R1、R2及与它们相连的碳一起形成C3-10杂环烷基时,所述C3-10杂环烷基中的杂原子的个数为1个;
和/或,当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2取代的C3-10杂环烷基中的C3-10杂环烷基为C4-6杂环烷基;
和/或,当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2取代的C3-10杂环烷基中的杂原子为N;
和/或,当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2取代的C3-10杂环烷基中的杂原子的个数为1;
和/或,当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2取代的C3-10杂环烷基中的C3-10杂环烷基为C4-6杂环烷基;
和/或,当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2的个数为1;
和/或,R3中,所述C6-30芳基和所述R3-1取代的C6-30芳基中的C6-30芳基独立地为C6-10芳基;
和/或,R3中,所述R3-1取代的C6-30芳基中的R3-1的个数为1;
和/或,R3中,所述R3-1取代的C6-30芳基中的R3-1取代位置为“芳基与其它基团连接位点”的对位;
和/或,R3-1中,所述直链C1-10烷基为直链C1-3烷基;
和/或,R3-1中,所述支链C3-10烷基为支链C3-4烷基;
和/或,R3-1中,所述C1-10烷氧基为C1-3烷氧基;
和/或,R3中,所述C3-30杂芳基为C6-10杂芳基;
和/或,R3中,所述C3-30杂芳基中的杂原子为O;
和/或,R3中,所述C3-30杂芳基中的杂原子的个数为1;
和/或,R3中,所述C2-10炔基为C4-7炔基;
和/或,R3中,所述R3-3取代的C2-10炔基中C2-10炔基为R3-3取代的C2-5炔基;
和/或,R3中,所述R3-3取代的C2-10炔基中的R3-3的个数为1;
和/或,R3-3中,所述卤素为Cl;
和/或,R3-3中,所述C2-10烯基为C2-3烯基;
和/或,R3-3中,所述C6-30芳基为C6-10芳基;
和/或,R3-4中,所述C6-30芳基为C6-10芳基;
和/或,R3-5a、R3-5b和R3-5c中,所述直链C1-10烷基独立地为直链C1-3烷基。
4.如权利要求3所述的制备方法,其特征在于,所述直链C1-10烷基为甲基、乙基或正丙基;
和/或,R1和R2中,所述C3-10环烷基为环丁基、环戊基、环己基或环庚基;
和/或,当R1、R2及与它们相连的碳一起形成C3-10杂环烷基时,所述C3-10杂环烷基为杂环己基;
和/或,当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2取代的C3-10杂环烷基中的C3-10杂环烷基为杂环己基;
和/或,当R1、R2及与它们相连的碳一起形成R2-2取代的C3-10杂环烷基时,所述R2-2取代的C3-10杂环烷基中的C3-10杂环烷基为哌啶基;
和/或,R3中,所述C6-30芳基和所述R3-1取代的C6-30芳基中的C6-30芳基独立地为苯基或萘基;
和/或,R3-1中,所述直链C1-10烷基为甲基;
和/或,R3-1中,所述支链C3-10烷基为异丙基;
和/或,R3-1中,所述C1-10烷氧基为甲氧基;
和/或,R3中,所述R3-3取代的C2-10炔基中C2-10炔基为R3-3取代的乙炔基、丙炔基、丁炔基或戊炔基;
和/或,R3-3中,所述C2-10烯基为乙烯基;
和/或,R3-3中,所述C6-30芳基为苯基;
和/或,R3-4中,所述C6-30芳基为苯基;
和/或,R3-5a、R3-5b和R3-5c中,所述直链C1-10烷基独立地为甲基。
5.如权利要求4所述的制备方法,其特征在于,
R1和R2中,所述直链C1-10烷基为甲基或乙基;
和/或,R1和R2中,所述C3-10环烷基为环己基或环庚基。
6.如权利要求2所述的制备方法,其特征在于,
R1、R2及与它们相连的碳一起形成C3-10杂环烷基,所述C3-10杂环烷基为“杂原子为O或N,个数为1或2个”的C4-10杂环烷基;
和/或,R3中,所述R3-1取代的C6-30芳基为“卤素、直链C1-10烷基、支链C3-10烷基或C1-10烷氧基,个数为1、2或3个,“芳基与其它基团连接位点”的邻位和/或对位”取代的C6-14芳基;
和/或,R3中,所述C3-30杂芳基为“杂原子为N或O,个数为1或2个”的C3-14杂芳基;
和/或,R3中,所述R3-3取代的C2-10炔基为“卤素、C2-10烯基、C6-30芳基或苯氧基,个数为1、2或3个”取代的C2-7炔基。
9.如权利要求1所述的制备方法,其特征在于,
R1和R2独立地为C1-10烷基或C3-10环烷基;
和/或,R1、R2及与它们相连的碳一起形成C3-10环烷基、C3-10杂环烷基或R2-2取代的C3-10杂环烷基;
和/或,R3-1取代的C6-30芳基中,所述R3-1独立地为卤素、直链C1-10烷基、支链C3-10烷基或C1-10烷氧基;
和/或,R3-3取代的C2-10炔基中,所述R3-3为卤素、C2-10烯基、C6-30芳基或苯氧基。
17.如权利要求1所述的制备方法,其特征在于,
所述保护气体为氖气、氩气、氪气、氙气和氡气中的一种或多种;
和/或,所述碱性试剂为六甲基二硅基胺基锂和/或碱金属醇盐;
和/或,所述钯催化剂为钯络合物;
和/或,所述有机溶剂为醚类溶剂、芳烃类溶剂和烷烃类溶剂中的一种或多种;
和/或,所述碱性试剂与所述化合物B的摩尔比值为0.1~0.5;
和/或,所述氮杂环卡宾配体与所述化合物B的摩尔比值为0.01-0.10;
和/或,所述钯催化剂与所述化合物B的摩尔比值为0.005~0.1;
和/或,所述化合物A与所述的化合物B的摩尔比值为1~5;
和/或,所述有机溶剂的体积与所述的化合物B的摩尔的体积摩尔比为10~20ml/mmol;
和/或,所述反应的温度为-30℃~50℃。
18.如权利要求17所述的制备方法,其特征在于,
所述保护气体为氮气和/或氩气;
和/或,所述碱性试剂与所述化合物B的摩尔比值为0.1~0.2;
和/或,所述氮杂环卡宾配体与所述化合物B的摩尔比值为0.02~0.08;
和/或,所述钯催化剂与所述化合物B的摩尔比值为0.01~0.04;
和/或,所述化合物A与所述的化合物B的摩尔比值为2~5;
和/或,所述反应的温度为-30℃~40℃。
19.如权利要求17所述的制备方法,其特征在于,
当所述碱性试剂为碱金属醇盐时,所述碱金属醇盐为RaONa、RbOK、RcOLi中的一种或多种,其中,Ra、Rb和Rc独立地为C1-4烷基;
和/或,当所述碱性试剂为碱金属碳酸盐时,所述碱金属碳酸盐为碳酸铯和/或碳酸钾;
和/或,当所述的氮杂环卡宾配体为非手性氮杂环卡宾配体时,所述非手性氮杂环卡宾配体为中一种或多种,其中,X1、X2和X3独立地为卤素、OTf或BF4;Rd1、Rd2、Rd3、Rd4、Rd5、Re1、Re2、Re3、Re4、Re5、Rf1、Rf2、Rf3、Rf4、Rf5、Rs1、Rs2、Rs3、Rs4和Rs5独立地为H、C1-10烷基或Ad为金刚烷基;
和/或,当所述的氮杂环卡宾配体为手性氮杂环卡宾配体时,所述手性氮杂环卡宾配体为 中一种或多种,其中,X4、X5、和X6独立地为卤素、OTf或BF4;Rm1、Rm2、Rm3、Rm4、Rm5、Rn1、Rn2、Rn3、Rn4、Rn5、Ro1、Ro2、Ro3、Rq1、Rq2或Rq3独立地为H、C1-10烷基、
和/或,当所述钯催化剂为钯络合物时,所述钯络合物为氯化烯丙基钯(II)二聚物、双二亚苄基丙酮钯、醋酸钯和氯化钯中的一种或多种;
和/或,当所述有机溶剂为醚类溶剂时,所述的醚类溶剂为四氢呋喃、乙二醇二甲醚、乙醚和二氧六环中的一种或多种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811602169.9A CN111362832B (zh) | 2018-12-26 | 2018-12-26 | 环丙烷类化合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811602169.9A CN111362832B (zh) | 2018-12-26 | 2018-12-26 | 环丙烷类化合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111362832A CN111362832A (zh) | 2020-07-03 |
CN111362832B true CN111362832B (zh) | 2022-10-04 |
Family
ID=71204027
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811602169.9A Active CN111362832B (zh) | 2018-12-26 | 2018-12-26 | 环丙烷类化合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111362832B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111960934A (zh) * | 2020-08-26 | 2020-11-20 | 辽宁科技大学 | 一种光引发剂1-羟基环己基苯基甲酮的合成方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1311773A (zh) * | 1998-06-08 | 2001-09-05 | 先灵公司 | 神经肽y5受体拮抗剂 |
-
2018
- 2018-12-26 CN CN201811602169.9A patent/CN111362832B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1311773A (zh) * | 1998-06-08 | 2001-09-05 | 先灵公司 | 神经肽y5受体拮抗剂 |
Non-Patent Citations (3)
Title |
---|
CAS RN1881845-75-5化合物;STN REGISTRY DATABASE;《STN REGISTRY DATABASE》;20160308 * |
Infrared spectra and structure of alkane- and cycloalkanecarbonitriles and of their carbanions: An ab initio force field treatment;Juchnovski, I.N. 等;《Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy》;19960831;第52卷(第9期);第1148页表2 * |
Synthesis and Pharmacological Characterization of Novel trans-Cyclopropylmethyl-Linked Bivalent Ligands That Exhibit Selectivity and Allosteric Pharmacology at the Dopamine D3 Receptor (D3R);Vivek Kumar 等;《Journal of Medicinal Chemistry》;20170210;第60卷(第4期);第1480页图解3 * |
Also Published As
Publication number | Publication date |
---|---|
CN111362832A (zh) | 2020-07-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110590841B (zh) | 一种氮磷配体及其制备方法和用途 | |
CN111362832B (zh) | 环丙烷类化合物及其制备方法和应用 | |
CN116514621B (zh) | 一种金属催化的硫叶立德与芳基硫/硒乙酸酯重排反应在芳基邻位构建c-c键的方法 | |
KR20150090207A (ko) | 자외선 흡수 화합물의 합성 | |
CA2764241C (en) | Disubstituted-aminodifluorosulfinium salts, process for preparing same and method of use as deoxofluorination reagents | |
CN103748065B (zh) | 2-烯基胺化合物的制造方法 | |
CN113024611B (zh) | 一种氮杂环卡宾环钯化合物及其制备方法和应用 | |
Bai et al. | Highly regio-and stereoselective palladium-catalyzed allene bifunctionalization cascade via π-allyl intermediate | |
Pinto et al. | Metal triflates combined with caffeine based imidazolium salts: A new family of highly efficient and reusable catalysts | |
CN108383754B (zh) | 一类芳基肟脂化合物的制备方法和应用 | |
CA2054821C (en) | Process for the production of 3-aminocrotononitrile | |
EP1955991A2 (en) | Preparation of organic compounds bearing a trifluoromethyl group on a quaternary carbon | |
CN113527130B (zh) | 一种α-酰胺,α-芳基季碳酮类化合物的合成方法 | |
CN105294416B (zh) | 一种1,5‑二羰基衍生物及其制备方法 | |
CN114835646B (zh) | 一种咪唑三氟甲硫基试剂及其合成应用 | |
KR102051053B1 (ko) | 옥소암모늄 염을 이용한 지방족 알데히드에서 나이트릴로의 산화적 전환법 | |
CN113173852B (zh) | 二氟丙二酸酯类化合物的制备方法 | |
KR101251625B1 (ko) | 새로운 중간체를 이용하는 두타스테라이드의 신규한 제조방법 | |
CN115710150A (zh) | 镍催化合成炔基取代环丙烷的方法 | |
CN109232249B (zh) | 一种多取代苯甲酸酯的制备方法 | |
JP6873488B2 (ja) | カルボン酸又はその塩の製造方法 | |
KR100841407B1 (ko) | 알리나인-1,6-다이올 유도체와 이의 제조방법 | |
CN116410213A (zh) | 一种合成3-碳基-1-硼基环类化合物的方法 | |
CN118221589A (zh) | 一种手性1,3-戊二烯基-5-(2h)-吲唑化合物的合成方法 | |
CN114262308A (zh) | 一类2-亚甲基-2,3-二氢噻唑类化合物及其合成方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |